

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/82, C07K 14/415, C12N 5/14, 15/63	A1	(11) International Publication Number: WO 00/68404 (43) International Publication Date: 16 November 2000 (16.11.00)
(21) International Application Number: PCT/US00/11086 (22) International Filing Date: 25 April 2000 (25.04.00) (30) Priority Data: 60/132,575 5 May 1999 (05.05.99) US (71) Applicant (for all designated States except US): PIONEER HI-BRED INTERNATIONAL, INC. [US/US]; 800 Capital Square, 400 Locust Street, Des Moines, IA 50309 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MAHAJAN, Pramod, B. [US/US]; 8029 Brookview Drive, Urbandale, IA 50022 (US). SHI, Jinrui [CN/US]; Apartment 205, 6022 Greendale Circle, Johnston, IA 50131 (US). (74) Agents: CIGAN, Amy, L. et al.; Darwin Building, 7100 N.W. 62nd Avenue, Johnston, IA 50131-1000 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: MAIZE RAD50 ORTHOLOGUE AND USES THEREOF		
(57) Abstract The invention provides isolated maize Rad50 nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering Rad50 levels in plants. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Maize Rad50 Orthologue and Uses Thereof

TECHNICAL FIELD

The present invention relates generally to plant molecular biology. More specifically, it relates to nucleic acids and methods for modulating their expression in plants.

BACKGROUND OF THE INVENTION

The RAD50 gene of *Saccharomyces cerevisiae* plays a crucial role in meiotic recombination as well as DNA repair during vegetative growth (Kupiec, M. and Simchen, G., *Mol. Gen. Genet.* 193: 525-531, 1984). The yeast RAD50 gene encodes a 153 kDa protein (Rad50) that contains an ATP- binding site (Walker -B box or P-loop) in the N-terminal region and exhibits ATP-dependent DNA binding *in vitro* (Raymond, W.E. and Kleckner, N., *Nucleic Acid Res.* 16: 3851-3856, 1993). The Rad50 protein also exhibits two, 250 amino acid segments of heptad-repeat sequence, which form alpha helical coiled coil structures (Alani *et al.*, *Genetics* 122: 47-57, 1989). In yeast, RAD50 deletion mutants show a mitotic hyper-recombinational phenotype. The same mutant exhibits reduced meiotic double strand break formation and recombination (reviewed in Malkova *et al.*, *Genetics* 143: 741-754, 1996 and Jeggo, P., *Radiation Res.* 150: S80-S91, 1998).

Interestingly, similar phenotypes were observed in the deletion mutants for two other yeast genes MRE11 and XRS2, suggesting an involvement of these genes in double-strand break repair and homologous recombination (Malkova *et al.*, *Genetics* 143: 741-754, 1996; Jeggo, P., *Radiation Res.* 150: S80-S91, 1998). Subsequently, Jozhuka and Ogawa demonstrated the interaction of yeast Rad50 and Mre11 proteins (Johzuka, K. and Ogawa, H., *Genetics* 139: 1521-1532, 1995). Tsukamoto *et al.*, showed the involvement of yeast RAD50, MER11 and XRS2 as well as HDF1 (yeast homologue of Ku70) in illegitimate or non-homologous end-joining (Tsukamoto, Y. *et al.*, *Mol. Gen. Genet.* 255: 543-547, 1997).

Recently, mammalian homologues of yeast RAD50 have been cloned and characterized extensively (Kim, K., *et al.*, *J. Biol. Chem.*, 271: 29255-29264, 1996; Dolganov *et al.*, *Mol. Cell. Biol.* 16: 4832-4841, 1996; Carney J.P. *et al.*, *Cell* 93: 477-486, 1998; Trujillo, K.M. *et al.*, *J. Biol. Chem.* 273: 21447-21450, 1998). Similarly, the *Arabidopsis thaliana* chromosome II BACF22D22 region (Accession No. AC006223) has

been found to contain an open reading frame which encodes a protein with homology to yeast RAD50 (GI:4263721).

Control of homologous recombination or non-homologous end joining by modulating Rad50 provides the means to modulate the efficiency with which heterologous nucleic acids are incorporated into the genomes of a target plant cell. Control of these processes has important implications in the creation of novel recombinantly engineered crops such as maize. The present invention provides this and other advantages.

SUMMARY OF THE INVENTION

The present invention describes the maize Rad50 protein, which clearly possesses features characteristic of other Rad50 proteins, and has a calculated molecular weight of ~152.5 kDa. The maize Rad50 protein is characterized by the presence of an ATP binding site in the N-terminal region, a second nucleotide binding site in the C-terminal region, putative nuclear localization signals, and heptad-repeats. The presence of extensive leucine zipper structures appears to be another striking feature of the Rad50 proteins. These are also found in the maize Rad50 protein and are indicated in **bold** in Figure 1. The present invention also describes a maize Rad50 polynucleotide sequence. The maize Rad50 orthologue of the present invention was used as a probe to map the maize RAD50 gene(s) to the short arm of chromosome 4.

Generally, it is the object of the present invention to provide nucleic acids and proteins relating to maize Rad50. It is an object of the present invention to provide: 1) antigenic fragments of the proteins of the present invention; 2) transgenic plants comprising the nucleic acids of the present invention; 3) methods for modulating, in a transgenic plant, the expression of the nucleic acids of the present invention.

Therefore, in one aspect, the present invention relates to an isolated nucleic acid comprising a member selected from the group consisting of (a) a polynucleotide having a specified sequence identity to a polynucleotide encoding a polypeptide of the present invention; (b) a polynucleotide which is complementary to the polynucleotide of (a); and, (c) a polynucleotide comprising a specified number of contiguous nucleotides from a polynucleotide of (a) or (b). The isolated nucleic acid can be DNA.

In another aspect, the present invention relates to recombinant expression cassettes, comprising a nucleic acid of the present invention operably linked to a promoter.

In another aspect, the present invention is directed to a host cell into which has been introduced the recombinant expression cassette.

In a further aspect, the present invention relates to an isolated protein comprising a polypeptide having a specified number of contiguous amino acids encoded by an isolated
5 nucleic acid of the present invention.

In another aspect, the present invention relates to an isolated nucleic acid comprising a polynucleotide of specified length which selectively hybridizes under stringent conditions to a polynucleotide of the present invention, or a complement thereof. In some embodiments, the isolated nucleic acid is operably linked to a promoter.

10 In another aspect, the present invention relates to a recombinant expression cassette comprising a nucleic acid amplified from a library as referred to *supra*, wherein the nucleic acid is operably linked to a promoter. In some embodiments, the present invention relates to a host cell transfected with this recombinant expression cassette. In some embodiments, the present invention relates to a protein of the present invention that is produced from this
15 host cell.

In yet another aspect, the present invention relates to a transgenic plant comprising a recombinant expression cassette comprising a plant promoter operably linked to any of the isolated nucleic acids of the present invention. The present invention also provides transgenic seed from the transgenic plant.

20

Definitions

Units, prefixes, and symbols may be denoted in their SI accepted form. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively. Numeric
25 ranges are inclusive of the numbers defining the range and include each integer within the defined range. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes. Unless otherwise provided for, software,
30 electrical, and electronics terms as used herein are as defined in The New IEEE Standard Dictionary of Electrical and Electronics Terms (5th edition, 1993). The terms defined below are more fully defined by reference to the specification as a whole.

By "amplified" is meant the construction of multiple copies of a nucleic acid sequence or multiple copies complementary to the nucleic acid sequence using at least one of the nucleic acid sequences as a template. Amplification systems include the polymerase chain reaction (PCR) system, ligase chain reaction (LCR) system, nucleic acid sequence
5 based amplification (NASBA, Cangene, Mississauga, Ontario), Q-Beta Replicase systems, transcription-based amplification system (TAS), and strand displacement amplification (SDA). See, e.g., *Diagnostic Molecular Microbiology: Principles and Applications*, D. H. Persing *et al.*, Ed., American Society for Microbiology, Washington, D.C. (1993). The product of amplification is termed an amplicon.

10 The term "antibody" includes reference to antigen binding forms of antibodies (e.g., Fab, F(ab)₂). The term "antibody" frequently refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind and recognize an analyte (antigen). However, while various antibody fragments can be defined in terms of the digestion of an intact antibody, one of skill will
15 appreciate that such fragments may be synthesized *de novo* either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments such as single chain Fv, chimeric antibodies (i.e., comprising constant and variable regions from different species), humanized antibodies (i.e., comprising a complementarity determining region (CDR) from a non-human source) and
20 heteroconjugate antibodies (e.g., bispecific antibodies).

The term "antigen" includes reference to a substance to which an antibody can be generated and/or to which the antibody is specifically immunoreactive. The specific immunoreactive sites within the antigen are known as epitopes or antigenic determinants. These epitopes can be a linear array of monomers in a polymeric composition - such as
25 amino acids in a protein - or consist of or comprise a more complex secondary or tertiary structure. Those of skill will recognize that all immunogens (i.e., substances capable of eliciting an immune response) are antigens; however some antigens, such as haptens, are not immunogens but may be made immunogenic by coupling to a carrier molecule. An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by
30 recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. See, e.g., Huse *et al.*, *Science* 246: 1275-1281 (1989); and Ward, *et al.*, *Nature* 341: 544-546 (1989); and Vaughan *et al.*, *Nature Biotech.* 14: 309-314 (1996).

As used herein, "antisense orientation" includes reference to a duplex polynucleotide sequence that is operably linked to a promoter in an orientation where the antisense strand is transcribed. The antisense strand is sufficiently complementary to an endogenous transcription product such that translation of the endogenous transcription product is often inhibited.

As used herein, "chromosomal region" includes reference to a length of a chromosome that may be measured by reference to the linear segment of DNA that it comprises. The chromosomal region can be defined by reference to two unique DNA sequences, i.e., markers.

The term "conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or conservatively modified variants of the amino acid sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations" and represent one species of conservatively modified variation. Every nucleic acid sequence herein that encodes a polypeptide also, by reference to the genetic code, describes every possible silent variation of the nucleic acid. One of ordinary skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine; and UGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide of the present invention is implicit in each described polypeptide sequence and is within the scope of the present invention.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Thus, any number of amino acid residues selected from the group of integers consisting of from 1 to 15 can be so altered. Thus, for example, 1, 2, 3, 4, 5, 7, or 10 alterations can be made.

Conservatively modified variants typically provide similar biological activity as the unmodified polypeptide sequence from which they are derived. For example, substrate specificity, enzyme activity, or ligand/receptor binding is generally at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the native protein for its native substrate. Conservative substitution tables providing functionally similar amino acids are well known in the art.

The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 10 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

See also, Creighton (1984) *Proteins* W.H. Freeman and Company.

15 By "encoding" or "encoded", with respect to a specified nucleic acid, is meant comprising the information for translation into the specified protein. A nucleic acid encoding a protein may comprise non-translated sequences (e.g., introns) within translated regions of the nucleic acid, or may lack such intervening non-translated sequences (e.g., as in cDNA). The information by which a protein is encoded is specified by the use of

20 codons. Typically, the amino acid sequence is encoded by the nucleic acid using the "universal" genetic code. However, variants of the universal code, such as are present in some plant, animal, and fungal mitochondria, the bacterium *Mycoplasma capricolum*, or the ciliate *Macronucleus*, may be used when the nucleic acid is expressed therein.

When the nucleic acid is prepared or altered synthetically, advantage can be taken

25 of known codon preferences of the intended host where the nucleic acid is to be expressed. For example, although nucleic acid sequences of the present invention may be expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of monocotyledons or dicotyledons as these preferences have been shown to differ (Murray *et al. Nucl. Acids*

30 *Res.* 17: 477-498 (1989)). Thus, the maize preferred codon for a particular amino acid may be derived from known gene sequences from maize. Maize codon usage for 28 genes from maize plants are listed in Table 4 of Murray *et al., supra*.

As used herein "full-length sequence" in reference to a specified polynucleotide or its encoded protein means having the entire amino acid sequence of, a native (non-synthetic), endogenous, biologically active form of the specified protein. Methods to determine whether a sequence is full-length are well known in the art including such exemplary techniques as northern or western blots, primer extension, S1 protection, and ribonuclease protection. See, e.g., *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997). Comparison to known full-length homologous (orthologous and/or paralogous) sequences can also be used to identify full-length sequences of the present invention. Additionally, consensus sequences typically present at the 5' and 3' untranslated regions of mRNA aid in the identification of a polynucleotide as full-length. For example, the consensus sequence ANNNNAAUGG, where the underlined codon represents the N-terminal methionine, aids in determining whether the polynucleotide has a complete 5' end. Consensus sequences at the 3' end, such as polyadenylation sequences, aid in determining whether the polynucleotide has a complete 3' end.

As used herein, "heterologous" in reference to a nucleic acid is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form. A heterologous protein may originate from a foreign species or, if from the same species, is substantially modified from its original form by deliberate human intervention.

By "host cell" is meant a cell which contains a vector and supports the replication and/or expression of the vector. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells. Preferably, host cells are monocotyledonous or dicotyledonous plant cells. A particularly preferred monocotyledonous host cell is a maize host cell.

The term "hybridization complex" includes reference to a duplex nucleic acid structure formed by two single-stranded nucleic acid sequences selectively hybridized with each other.

By "immunologically reactive conditions" or "immunoreactive conditions" is meant conditions which allow an antibody, reactive to a particular epitope, to bind to that epitope

to a detectably greater degree (e.g., at least 2-fold over background) than the antibody binds to substantially any other epitopes in a reaction mixture comprising the particular epitope. Immunologically reactive conditions are dependent upon the format of the antibody binding reaction and typically are those utilized in immunoassay protocols. See
5 Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York (1988), for a description of immunoassay formats and conditions.

The term "introduced" in the context of inserting a nucleic acid into a cell, means "transfection" or "transformation" or "transduction" and includes reference to the incorporation of a nucleic acid into a eukaryotic or prokaryotic cell where the nucleic acid
10 may be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).

The terms "isolated" refers to material, such as a nucleic acid or a protein, which is: (1) substantially or essentially free from components that normally accompany or interact
15 with it as found in its naturally occurring environment. The isolated material optionally comprises material not found with the material in its natural environment; or (2) if the material is in its natural environment, the material has been synthetically (non-naturally) altered by deliberate human intervention to a composition and/or placed at a location in the cell (e.g., genome or subcellular organelle) not native to a material found in that
20 environment. The alteration to yield the synthetic material can be performed on the material within or removed from its natural state. For example, a naturally occurring nucleic acid becomes an isolated nucleic acid if it is altered, or if it is transcribed from DNA which has been altered, by means of human intervention performed within the cell from which it originates. See, e.g., Compounds and Methods for Site Directed Mutagenesis
25 in Eukaryotic Cells, Kmiec, U.S. Patent No. 5,565,350; *In Vivo* Homologous Sequence Targeting in Eukaryotic Cells; Zarling *et al.*, PCT/US93/03868. Likewise, a naturally occurring nucleic acid (e.g., a promoter) becomes isolated if it is introduced by non-naturally occurring means to a locus of the genome not native to that nucleic acid. Nucleic acids which are "isolated" as defined herein, are also referred to as "heterologous" nucleic
30 acids.

Unless otherwise stated, the term "maize Rad50 nucleic acid" is a nucleic acid of the present invention and means a nucleic acid comprising a polynucleotide of the present invention (a "maize Rad50 polynucleotide") encoding a maize Rad50 polypeptide. A

"maize Rad50 gene" is a gene of the present invention and refers to a heterologous genomic form of a full-length maize Rad50 polynucleotide.

As used herein, "localized within the chromosomal region defined by and including" with respect to particular markers includes reference to a contiguous length of a chromosome delimited by and including the stated markers.

As used herein, "marker" includes reference to a locus on a chromosome that serves to identify a unique position on the chromosome. A "polymorphic marker" includes reference to a marker which appears in multiple forms (alleles) such that different forms of the marker, when they are present in a homologous pair, allow transmission of each of the chromosomes of that pair to be followed. A genotype may be defined by use of one or a plurality of markers.

As used herein, "nucleic acid" includes reference to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogues having the essential nature of natural nucleotides in that they hybridize to single-stranded nucleic acids in a manner similar to naturally occurring nucleotides (e.g., peptide nucleic acids).

By "nucleic acid library" is meant a collection of isolated DNA or RNA molecules which comprise and substantially represent the entire transcribed fraction of a genome of a specified organism. Construction of exemplary nucleic acid libraries, such as genomic and cDNA libraries, is taught in standard molecular biology references such as Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology*, Vol. 152, Academic Press, Inc., San Diego, CA (Berger); Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, 2nd ed., Vol. 1-3 (1989); and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, Eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1994).

As used herein "operably linked" includes reference to a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

As used herein, the term "plant" includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. Plant cell, as

used herein includes, without limitation, seeds, suspension cultures, embryos, meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants. A particularly preferred plant is *Zea mays*.

As used herein, "polynucleotide" includes reference to a deoxyribopolynucleotide, ribopolynucleotide, or analogs thereof that have the essential nature of a natural ribonucleotide in that they hybridize, under stringent hybridization conditions, to substantially the same nucleotide sequence as naturally occurring nucleotides and/or allow translation into the same amino acid(s) as the naturally occurring nucleotide(s). A polynucleotide can be full-length or a subsequence of a native or heterologous structural or regulatory gene. Unless otherwise indicated, the term includes reference to the specified sequence as well as the complementary sequence thereof. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including among other things, simple and complex cells.

The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The essential nature of such analogues of naturally occurring amino acids is that, when incorporated into a protein, that protein is specifically reactive to antibodies elicited to the same protein but consisting entirely of naturally occurring amino acids. The terms "polypeptide", "peptide" and "protein" are also inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation. It will be appreciated, as is well known and

as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular,
5 branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well. Further, this invention contemplates the use of both the methionine-containing and the methionine-less amino terminal variants of the protein of the invention.

As used herein "promoter" includes reference to a region of DNA upstream from
10 the start of transcription and involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating transcription in plant cells whether or not its origin is a plant cell. Exemplary plant promoters include, but are not limited to, those that are obtained from plants, plant viruses, and bacteria which comprise genes expressed in plant cells such *Agrobacterium* or
15 *Rhizobium*. Examples of promoters under developmental control include promoters that preferentially initiate transcription in certain tissues, such as leaves, roots, or seeds. Such promoters are referred to as "tissue preferred". Promoters which initiate transcription only in certain tissue are referred to as "tissue specific". A "cell type" specific promoter primarily drives expression in certain cell types in one or more organs, for example,
20 vascular cells in roots or leaves. An "inducible" or "repressible" promoter is a promoter which is under environmental control. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions or the presence of light. Tissue specific, tissue preferred, cell type specific, and inducible promoters constitute the class of "non-constitutive" promoters. A "constitutive" promoter is a
25 promoter which is active under most environmental conditions.

The term "maize Rad50 polypeptide" is a polypeptide of the present invention and refers to one or more amino acid sequences, in glycosylated or non-glycosylated form. The term is also inclusive of fragments, variants, homologs, alleles or precursors (e.g., preproproteins or proproteins) thereof. A "maize Rad50 protein" is a protein of the present
30 invention and comprises a maize Rad50 polypeptide.

As used herein "recombinant" includes reference to a cell or vector, that has been modified by the introduction of a heterologous nucleic acid or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found

in identical form within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under-expressed or not expressed at all as a result of deliberate human intervention. The term "recombinant" as used herein does not encompass the alteration of the cell or vector by naturally occurring events (e.g., spontaneous mutation, natural transformation/transduction/transposition) such as those occurring without deliberate human intervention.

As used herein, a "recombinant expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a host cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid to be transcribed, and a promoter.

The term "residue" or "amino acid residue" or "amino acid" are used interchangeably herein to refer to an amino acid that is incorporated into a protein, polypeptide, or peptide (collectively "protein"). The amino acid may be a naturally occurring amino acid and, unless otherwise limited, may encompass non-natural analogs of natural amino acids that can function in a similar manner as naturally occurring amino acids.

The term "selectively hybridizes" includes reference to hybridization, under stringent hybridization conditions, of a nucleic acid sequence to a specified nucleic acid target sequence to a detectably greater degree (e.g., at least 2-fold over background) than its hybridization to non-target nucleic acid sequences and to the substantial exclusion of non-target nucleic acids. Selectively hybridizing sequences typically have about at least 80% sequence identity, preferably 90% sequence identity, and most preferably 100% sequence identity (i.e., complementary) with each other.

The term "specifically reactive", includes reference to a binding reaction between an antibody and a protein having an epitope recognized by the antigen binding site of the antibody. This binding reaction is determinative of the presence of a protein having the recognized epitope amongst the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to an analyte having the recognized epitope to a substantially greater degree (e.g., at

least 2-fold over background) than to substantially all analytes lacking the epitope which are present in the sample.

Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies raised to the polypeptides of the present invention can be selected from to obtain antibodies specifically reactive with polypeptides of the present invention. The proteins used as immunogens can be in native conformation or denatured so as to provide a linear epitope.

A variety of immunoassay formats may be used to select antibodies specifically reactive with a particular protein (or other analyte). For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York (1988), for a description of immunoassay formats and conditions that can be used to determine selective reactivity.

The term "stringent conditions" or "stringent hybridization conditions" includes reference to conditions under which a probe will hybridize to its target sequence, to a detectably greater degree than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences can be identified which are 100% complementary to the probe (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, optionally less than 500 nucleotides in length.

Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37°C, and a wash in 1X to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to 1X SSC at 55 to

60°C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1X SSC at 60 to 65°C.

Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T_m can be approximated from the equation of Meinkoth and Wahl, *Anal. Biochem.*, 138:267-284 (1984): $T_m = 81.5\text{ }^{\circ}\text{C} + 16.6 (\log M) + 0.41 (\%GC) - 0.61 (\% \text{ form}) - 500/L$; where M is the molarity of monovalent cations, %GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T_m is reduced by about 1 °C for each 1% of mismatching; thus, T_m , hybridization and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with $\geq 90\%$ identity are sought, the T_m can be decreased 10 °C. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point (T_m) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4 °C lower than the thermal melting point (T_m); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10 °C lower than the thermal melting point (T_m); low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20 °C lower than the thermal melting point (T_m). Using the equation, hybridization and wash compositions, and desired T_m , those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T_m of less than 45 °C (aqueous solution) or 32 °C (formamide solution) it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes*, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York (1993); and *Current Protocols in Molecular Biology*, Chapter 2, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995).

As used herein, "transgenic plant" includes reference to a plant which comprises within its genome a heterologous polynucleotide. Generally, the heterologous

polynucleotide is stably integrated within the genome such that the polynucleotide is passed on to successive generations. The heterologous polynucleotide may be integrated into the genome alone or as part of a recombinant expression cassette. "Transgenic" is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acid including those transgenics initially so altered as well as those created by sexual crosses or asexual propagation from the initial transgenic. The term "transgenic" as used herein does not encompass the alteration of the genome (chromosomal or extra-chromosomal) by conventional plant breeding methods or by naturally occurring events such as random cross-fertilization, non-recombinant viral infection, non-recombinant bacterial transformation, non-recombinant transposition, or spontaneous mutation.

As used herein, "vector" includes reference to a nucleic acid used in transfection of a host cell and into which can be inserted a polynucleotide. Vectors are often replicons. Expression vectors permit transcription of a nucleic acid inserted therein.

The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) "reference sequence", (b) "comparison window", (c) "sequence identity", (d) "percentage of sequence identity", and (e) "substantial identity".

(a) As used herein, "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.

(b) As used herein, "comparison window" includes reference to a contiguous and specified segment of a polynucleotide/polypeptide sequence, wherein the polynucleotide/polypeptide sequence may be compared to a reference sequence and wherein the portion of the polynucleotide/polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Generally, the comparison window is at least 20 contiguous nucleotides/amino acids residues in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide/polypeptide sequence, a gap penalty is typically introduced and is subtracted from the number of matches.

Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman, *Adv. Appl. Math.* 2: 482 (1981); by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48: 443 (1970); by the
5 search for similarity method of Pearson and Lipman, *Proc. Natl. Acad. Sci.* 85: 2444 (1988); by computerized implementations of these algorithms, including, but not limited to: CLUSTAL in the PC/Gene program by Intelligenetics, Mountain View, California; GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wisconsin, USA;
10 the CLUSTAL program is well described by Higgins and Sharp, *Gene* 73: 237-244 (1988); Higgins and Sharp, *CABIOS* 5: 151-153 (1989); Corpet, *et al.*, *Nucleic Acids Research* 16: 10881-90 (1988); Huang, *et al.*, *Computer Applications in the Biosciences* 8: 155-65 (1992), and Pearson, *et al.*, *Methods in Molecular Biology* 24: 307-331 (1994).

The BLAST family of programs which can be used for database similarity searches
15 includes: BLASTN for nucleotide query sequences against nucleotide database sequences; BLASTX for nucleotide query sequences against protein database sequences; BLASTP for protein query sequences against protein database sequences; TBLASTN for protein query sequences against nucleotide database sequences; and TBLASTX for nucleotide query sequences against nucleotide database sequences. See, *Current Protocols in Molecular*
20 *Biology*, Chapter 19, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995).

Software for performing BLAST analyses is publicly available, e.g., through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short
25 words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold. These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as
30 the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the

word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (*see* Henikoff & Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915).

10 In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (*see, e.g.,* Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5877 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.

BLAST searches assume that proteins can be modeled as random sequences. However, many real proteins comprise regions of nonrandom sequences which may be homopolymeric tracts, short-period repeats, or regions enriched in one or more amino acids. Such low-complexity regions may be aligned between unrelated proteins even though other regions of the protein are entirely dissimilar. A number of low-complexity filter programs can be employed to reduce such low-complexity alignments. For example, the SEG (Wooten and Federhen, *Comput. Chem.*, 17:149-163 (1993)) and XNU (Claverie and States, *Comput. Chem.*, 17:191-201 (1993)) low-complexity filters can be employed alone or in combination.

25 GAP can also be used to compare a polynucleotide or polypeptide of the present invention with a reference sequence. GAP uses the algorithm of Needleman and Wunsch (*J. Mol. Biol.* 48: 443-453, 1970) to find the alignment of two complete sequences that maximizes the number of matches and minimizes the number of gaps. GAP considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. It allows for the provision of a gap creation penalty and a gap extension penalty in units of matched bases. GAP must make a profit of gap creation penalty number of matches for each gap it inserts. If a gap extension penalty greater than zero is chosen, GAP must, in addition, make a profit for each gap inserted of

the length of the gap times the gap extension penalty. Default gap creation penalty values and gap extension penalty values in Version 10 of the Wisconsin Genetics Software Package for protein sequences are 8 and 2, respectively. For nucleotide sequences the default gap creation penalty is 50 while the default gap extension penalty is 3. The gap
5 creation and gap extension penalties can be expressed as an integer selected from the group of integers consisting of from 0 to 200. Thus, for example, the gap creation and gap extension penalties can each independently be: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 65 or greater.

GAP presents one member of the family of best alignments. There may be many
10 members of this family, but no other member has a better quality. GAP displays four figures of merit for alignments: Quality, Ratio, Identity, and Similarity. The Quality is the metric maximized in order to align the sequences. Ratio is the quality divided by the number of bases in the shorter segment. Percent Identity is the percent of the symbols that actually match. Percent Similarity is the percent of the symbols that are similar. Symbols
15 that are across from gaps are ignored. A similarity is scored when the scoring matrix value for a pair of symbols is greater than or equal to 0.50, the similarity threshold. The scoring matrix used in Version 10 of the Wisconsin Genetics Software Package is BLOSUM62 (see Henikoff & Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915).

Unless otherwise stated, sequence identity/similarity values provided herein refer to
20 the value obtained using the BLAST 2.0 suite of programs using default parameters (Altschul *et al.*, *Nucleic Acids Res.* 25:3389-3402, 1997; Altschul *et al.*, *J. Mol. Bio.* 215: 403-410, 1990) or to the value obtained using the GAP program using default parameters (see the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wisconsin, USA).

25 (c) As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences includes reference to the residues in the two sequences which are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by
30 conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g. charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to

correct for the conservative nature of the substitution. Sequences which differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well-known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, *e.g.*, according to the algorithm of Meyers and Miller, *Computer Applic. Biol. Sci.*, 4: 11-17 (1988) *e.g.*, as implemented in the program PC/GENE (Intelligenetics, Mountain View, California, USA).

(d) As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

(e) (i) The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70% sequence identity, preferably at least 80%, more preferably at least 90% and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially

identical if the polypeptides which they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is that the polypeptide which the first nucleic acid encodes is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.

(e) (ii) The terms "substantial identity" in the context of a peptide indicates that a peptide comprises a sequence with at least 70% sequence identity to a reference sequence, preferably 80%, more preferably 85%, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window. Optionally, optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48: 443 (1970). An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Peptides which are "substantially similar" share sequences as noted above except that residue positions which are not identical may differ by conservative amino acid changes.

DETAILED DESCRIPTION OF THE INVENTION

Overview

The present invention provides, among other things, compositions and methods for modulating (i.e., increasing or decreasing) the level of polynucleotides and polypeptides of the present invention in plants. In particular, the polynucleotides and polypeptides of the present invention can be expressed temporally or spatially, e.g., at developmental stages, in tissues, and/or in quantities, which are uncharacteristic of non-recombinantly engineered plants. Thus, the present invention provides utility in such exemplary applications as in the control of recombination efficiency or transformation efficiency in plants.

The present invention also provides isolated nucleic acid comprising polynucleotides of sufficient length and complementarity to a gene of the present invention to use as probes or amplification primers in the detection, quantitation, or isolation of gene transcripts. For example, isolated nucleic acids of the present invention can be used as probes in detecting deficiencies in the level of mRNA in screenings for desired transgenic plants, for detecting mutations in the gene (e.g., substitutions, deletions, or additions), for monitoring upregulation of expression or changes in enzyme activity in screening assays of

- compounds, for detection of any number of allelic variants (polymorphisms), orthologs, or paralogs of the gene, or for site directed mutagenesis in eukaryotic cells (see, e.g., U.S. Patent No. 5,565,350). The isolated nucleic acids of the present invention can also be used for recombinant expression of their encoded polypeptides, or for use as immunogens in the preparation and/or screening of antibodies. The isolated nucleic acids of the present invention can also be employed for use in sense or antisense suppression of one or more genes of the present invention in a host cell, tissue, or plant. Attachment of chemical agents which bind, intercalate, cleave and/or crosslink to the isolated nucleic acids of the present invention can also be used to modulate transcription or translation.
- 10 The present invention also provides isolated proteins comprising a polypeptide of the present invention (e.g., preproenzyme, proenzyme, or enzymes). The present invention also provides proteins comprising at least one epitope from a polypeptide of the present invention. The proteins of the present invention can be employed in assays for enzyme agonists or antagonists of enzyme function, or for use as immunogens or antigens to obtain
- 15 antibodies specifically immunoreactive with a protein of the present invention. Such antibodies can be used in assays for expression levels, for identifying and/or isolating nucleic acids of the present invention from expression libraries, for identification of homologous polypeptides from other species, or for purification of polypeptides of the present invention.
- 20 The isolated nucleic acids and polypeptides of the present invention can be used over a broad range of plant types, particularly monocots such as the species of the family *Gramineae* including *Hordeum*, *Secale*, *Triticum*, *Sorghum* (e.g., *S. bicolor*), *Oryza*, *Avena*, and *Zea* (e.g., *Z. mays*). The isolated nucleic acid and proteins of the present invention can also be used in species from the genera: *Cucurbita*, *Rosa*, *Vitis*, *Juglans*,
- 25 *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Ciahorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemesis*, *Pelargonium*, *Panieum*, *Pennisetum*, *Ranunculus*, *Senecio*,
- 30 *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Pisum*, *Phaseolus*, and *Lolium*.

Nucleic Acids

The present invention provides, among other things, isolated nucleic acids of RNA, DNA, and analogs and/or chimeras thereof, comprising a polynucleotide of the present invention.

5 A polynucleotide of the present invention is inclusive of:

 (a) a polynucleotide encoding a polypeptide of SEQ ID NO: 2 and conservatively modified and polymorphic variants thereof, including exemplary polynucleotides of SEQ ID NO: 1; the polynucleotide sequence of the invention also includes the maize RAD50 polynucleotide sequence as contained in a plasmid deposited with American Type Culture
10 Collection (ATCC) and assigned Accession Number 207194.

 (b) a polynucleotide which is the product of amplification from a *Zea mays* nucleic acid library using primer pairs which selectively hybridize under stringent conditions to loci within the polynucleotide of SEQ ID NO: 1, or the sequence as contained in ATCC deposit assigned Accession No. 207194, wherein the polynucleotide has substantial
15 sequence identity to the polynucleotide of SEQ ID NO: 1; or the sequence as contained in ATCC deposit assigned Accession No. 207194.

 (c) a polynucleotide which selectively hybridizes to a polynucleotide of (a) or (b);

 (d) a polynucleotide having a specified sequence identity with polynucleotides of (a), (b), or (c);

20 (e) a polynucleotide encoding a protein having a specified number of contiguous amino acids from a prototype polypeptide, wherein the protein is specifically recognized by antisera elicited by presentation of the protein and wherein the protein does not detectably immunoreact to antisera which has been fully immunosorbed with the protein;

 (f) complementary sequences of polynucleotides of (a), (b), (c), (d), or (e); and

25 (g) a polynucleotide comprising at least a specific number of contiguous nucleotides from a polynucleotide of (a), (b), (c), (d), (e), or (f).

 The polynucleotide of SEQ ID NO: 1 is contained in a plasmid deposited with American Type Culture Collection (ATCC) on April 6, 1999 and assigned Accession Number 207194. American Type Culture Collection is located at 10801 University Blvd.,
30 Manassas, VA 20110-2209.

 The ATCC deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. The deposit is provided as a convenience to those of skill in the art and is not

an admission that a deposit is required under 35 U.S.C. Section 112. The deposited sequence, as well as the polypeptide encoded by the sequence, is incorporated herein by reference and controls in the event of any conflict, such as a sequencing error, with description in this application.

5

A. Polynucleotides Encoding A Polypeptide of the Present Invention or Conservatively Modified or Polymorphic Variants Thereof

As indicated in (a), above, the present invention provides isolated nucleic acids comprising a polynucleotide of the present invention, wherein the polynucleotide encodes a polypeptide of the present invention, or conservatively modified or polymorphic variants thereof. Accordingly, the present invention includes polynucleotides of SEQ ID NO: 1, and the sequence as contained in ATCC deposit assigned Accession No. 207194, and silent variations of polynucleotides encoding a polypeptide of SEQ ID NO: 2. The present invention further provides isolated nucleic acids comprising polynucleotides encoding conservatively modified variants of a polypeptide of SEQ ID NO: 2. Conservatively modified variants can be used to generate or select antibodies immunoreactive to the non-variant polypeptide. Additionally, the present invention further provides isolated nucleic acids comprising polynucleotides encoding one or more allelic (polymorphic) variants of polypeptides/polynucleotides. Polymorphic variants are frequently used to follow segregation of chromosomal regions in, for example, marker assisted selection methods for crop improvement.

B. Polynucleotides Amplified from a Zea mays Nucleic Acid Library

As indicated in (b), above, the present invention provides an isolated nucleic acid comprising a polynucleotide of the present invention, wherein the polynucleotides are amplified from a *Zea mays* nucleic acid library. *Zea mays* lines B73, PHRE1, A632, BMS-P2#10, W23, and Mo17 are known and publicly available. Other publicly known and available maize lines can be obtained from the Maize Genetics Cooperation (Urbana, IL). The nucleic acid library may be a cDNA library, a genomic library, or a library generally constructed from nuclear transcripts at any stage of intron processing. cDNA libraries can be normalized to increase the representation of relatively rare cDNAs. In optional embodiments, the cDNA library is constructed using a full-length cDNA synthesis method. Examples of such methods include Oligo-Capping (Maruyama, K. and Sugano, S. *Gene*

30

138: 171-174, 1994), Biotinylated CAP Trapper (Carninci, P., Kvan, C., *et al. Genomics* 37: 327-336, 1996), and CAP Retention Procedure (Edery, E., Chu, L.L., *et al. Molecular and Cellular Biology* 15: 3363-3371, 1995). cDNA synthesis is often catalyzed at 50-

55°C to prevent formation of RNA secondary structure. Examples of reverse

- 5 transcriptases that are relatively stable at these temperatures are SUPERScript II Reverse Transcriptase (Life Technologies, Inc.), AMV Reverse Transcriptase (Boehringer Mannheim) and RETROAMP Reverse Transcriptase (Epicentre). Rapidly growing tissues, or rapidly dividing cells are preferably used as mRNA sources.

- The present invention also provides subsequences of the polynucleotides of the
- 10 present invention. A variety of subsequences can be obtained using primers which selectively hybridize under stringent conditions to at least two sites within a polynucleotide of the present invention, or to two sites within the nucleic acid which flank and comprise a polynucleotide of the present invention, or to a site within a polynucleotide of the present invention and a site within the nucleic acid which comprises it. Primers are chosen to
- 15 selectively hybridize, under stringent hybridization conditions, to a polynucleotide of the present invention. Generally, the primers are complementary to a subsequence of the target nucleic acid which they amplify. As those skilled in the art will appreciate, the sites to which the primer pairs will selectively hybridize are chosen such that a single contiguous nucleic acid can be formed under the desired amplification conditions. In
- 20 optional embodiments, the primers will be constructed so that they selectively hybridize under stringent conditions to a sequence (or its complement) within the target nucleic acid which comprises the codon encoding the carboxy or amino terminal amino acid residue (i.e., the 3' terminal coding region and 5' terminal coding region, respectively) of the polynucleotides of the present invention. Optionally within these embodiments, the
- 25 primers will be constructed to selectively hybridize entirely within the coding region of the target polynucleotide of the present invention such that the product of amplification of a cDNA target will consist of the coding region of that cDNA. The primer length in nucleotides is selected from the group of integers consisting of from at least 15 to 50. Thus, the primers can be at least 15, 18, 20, 25, 30, 40, or 50 nucleotides in length. Those
- 30 of skill will recognize that a lengthened primer sequence can be employed to increase specificity of binding (i.e., annealing) to a target sequence. A non-annealing sequence at the 5' end of a primer (a "tail") can be added, for example, to introduce a cloning site at the terminal ends of the amplicon.

The amplification products can be translated using expression systems well known to those of skill in the art and as discussed, *infra*. The resulting translation products can be confirmed as polypeptides of the present invention by, for example, assaying for the appropriate catalytic activity (e.g., specific activity and/or substrate specificity), or
5 verifying the presence of one or more linear epitopes which are specific to a polypeptide of the present invention. Methods for protein synthesis from PCR derived templates are known in the art and available commercially. See, e.g., Amersham Life Sciences, Inc, Catalog '97, p.354.

Methods for obtaining 5' and/or 3' ends of a vector insert are well known in the art.
10 See, e.g., RACE (Rapid Amplification of Complementary Ends) as described in Frohman, M. A., in PCR Protocols: A Guide to Methods and Applications, M. A. Innis, D. H. Gelfand, J. J. Sninsky, T. J. White, Eds. (Academic Press, Inc., San Diego), pp. 28-38 (1990)); see also, U.S. Pat. No. 5,470,722, and *Current Protocols in Molecular Biology*, Unit 15.6, Ausubel, *et al.*, Eds, Greene Publishing and Wiley-Interscience, New York
15 (1995); Frohman and Martin, *Techniques* 1:165 (1989).

C. Polynucleotides Which Selectively Hybridize to a Polynucleotide of (A) or (B)

As indicated in (c), above, the present invention provides isolated nucleic acids comprising polynucleotides of the present invention, wherein the polynucleotides
20 selectively hybridize, under selective hybridization conditions, to a polynucleotide of sections (A) or (B) as discussed above. Thus, the polynucleotides of this embodiment can be used for isolating, detecting, and/or quantifying nucleic acids comprising the polynucleotides of (A) or (B). For example, polynucleotides of the present invention can be used to identify, isolate, or amplify partial or full-length clones in a deposited library. In
25 some embodiments, the polynucleotides are genomic or cDNA sequences isolated or otherwise complementary to a cDNA from a dicot or monocot nucleic acid library. Exemplary species of monocots and dicots include, but are not limited to: corn, canola, soybean, cotton, wheat, sorghum, sunflower, oats, sugar cane, millet, barley, and rice. Optionally, the cDNA library comprises at least 80% full-length sequences, preferably at
30 least 85% or 90% full-length sequences, and more preferably at least 95% full-length sequences. The cDNA libraries can be normalized to increase the representation of rare sequences. Low stringency hybridization conditions are typically, but not exclusively, employed with sequences having a reduced sequence identity relative to complementary

sequences. Moderate and high stringency conditions can optionally be employed for sequences of greater identity. Low stringency conditions allow selective hybridization of sequences having about 70% sequence identity and can be employed to identify orthologous or paralogous sequences.

5

D. Polynucleotides Having a Specific Sequence Identity with the Polynucleotides of (A), (B) or (C)

As indicated in (d), above, the present invention provides isolated nucleic acids comprising polynucleotides of the present invention, wherein the polynucleotides have a specified identity at the nucleotide level to a polynucleotide as disclosed above in sections (A), (B), or (C), above. The percentage of identity to a reference sequence is at least 60% and, rounded upwards to the nearest integer, can be expressed as an integer selected from the group of integers consisting of from 60 to 99. Thus, for example, the percentage of identity to a reference sequence can be at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

Optionally, the polynucleotides of this embodiment will encode a polypeptide that will share an epitope with a polypeptide encoded by the polynucleotides of sections (A), (B), or (C). Thus, these polynucleotides encode a first polypeptide which elicits production of antisera comprising antibodies which are specifically reactive to a second polypeptide encoded by a polynucleotide of (A), (B), or (C). However, the first polypeptide does not bind to antisera raised against itself when the antisera has been fully immunosorbed with the first polypeptide. Hence, the polynucleotides of this embodiment can be used to generate antibodies for use in, for example, the screening of expression libraries for nucleic acids comprising polynucleotides of (A), (B), or (C), or for purification of, or in immunoassays for, polypeptides encoded by the polynucleotides of (A), (B), or (C). The polynucleotides of this embodiment embrace nucleic acid sequences which can be employed for selective hybridization to a polynucleotide encoding a polypeptide of the present invention.

Screening polypeptides for specific binding to antisera can be conveniently achieved using peptide display libraries. This method involves the screening of large collections of peptides for individual members having the desired function or structure. Antibody screening of peptide display libraries is well known in the art. The displayed peptide sequences can be from 3 to 5000 or more amino acids in length, frequently from 5-

100 amino acids long, and often from about 8 to 15 amino acids long. In addition to direct chemical synthetic methods for generating peptide libraries, several recombinant DNA methods have been described. One type involves the display of a peptide sequence on the surface of a bacteriophage or cell. Each bacteriophage or cell contains the nucleotide
5 sequence encoding the particular displayed peptide sequence. Such methods are described in PCT patent publication Nos. 91/17271, 91/18980, 91/19818, and 93/08278. Other systems for generating libraries of peptides have aspects of both *in vitro* chemical synthesis and recombinant methods. See, PCT Patent publication Nos. 92/05258, 92/14843, and 96/19256. See also, U.S. Patent Nos. 5,658,754; and 5,643,768. Peptide display libraries,
10 vectors, and screening kits are commercially available from such suppliers as Invitrogen (Carlsbad, CA).

E. Polynucleotides Encoding a Protein Having a Subsequence from a Prototype Polypeptide and is Cross-Reactive to the Prototype Polypeptide

15 As indicated in (e), above, the present invention provides isolated nucleic acids comprising polynucleotides of the present invention, wherein the polynucleotides encode a protein having a subsequence of contiguous amino acids from a prototype polypeptide of the present invention such as are provided in (a), above. The length of contiguous amino acids from the prototype polypeptide is selected from the group of integers consisting of
20 from at least 10 to the number of amino acids within the prototype sequence. Thus, for example, the polynucleotide can encode a polypeptide having a subsequence having at least 10, 15, 20, 25, 30, 35, 40, 45, or 50, contiguous amino acids from the prototype polypeptide. Further, the number of such subsequences encoded by a polynucleotide of the instant embodiment can be any integer selected from the group consisting of from 1 to 20,
25 such as 2, 3, 4, or 5. The subsequences can be separated by any integer of nucleotides from 1 to the number of nucleotides in the sequence such as at least 5, 10, 15, 25, 50, 100, or 200 nucleotides.

The proteins encoded by polynucleotides of this embodiment, when presented as an immunogen, elicit the production of polyclonal antibodies which specifically bind to a
30 prototype polypeptide such as but not limited to, a polypeptide encoded by the polynucleotide of (a) or (b), above. Generally, however, a protein encoded by a polynucleotide of this embodiment does not bind to antisera raised against the prototype polypeptide when the antisera has been fully immunosorbed with the prototype

polypeptide. Methods of making and assaying for antibody binding specificity/affinity are well known in the art. Exemplary immunoassay formats include ELISA, competitive immunoassays, radioimmunoassays, Western blots, indirect immunofluorescent assays and the like.

5 In a preferred assay method, fully immunosorbed and pooled antisera which is elicited to the prototype polypeptide can be used in a competitive binding assay to test the protein. The concentration of the prototype polypeptide required to inhibit 50% of the binding of the antisera to the prototype polypeptide is determined. If the amount of the protein required to inhibit binding is less than twice the amount of the prototype protein,
10 then the protein is said to specifically bind to the antisera elicited to the immunogen. Accordingly, the proteins of the present invention embrace allelic variants, conservatively modified variants, and minor recombinant modifications to a prototype polypeptide.

 A polynucleotide of the present invention optionally encodes a protein having a molecular weight as the non-glycosylated protein within 20% of the molecular weight of
15 the full-length non-glycosylated polypeptides of the present invention. Molecular weight can be readily determined by SDS-PAGE under reducing conditions. Optionally, the molecular weight is within 15% of a full length polypeptide of the present invention, more preferably within 10% or 5%, and most preferably within 3%, 2%, or 1% of a full length polypeptide of the present invention.

20 Optionally, the polynucleotides of this embodiment will encode a protein having a specific enzymatic activity at least 50%, 60%, 80%, or 90% of a cellular extract comprising the native, endogenous full-length polypeptide of the present invention. Further, the proteins encoded by polynucleotides of this embodiment will optionally have a substantially similar affinity constant (K_m) and/or catalytic activity (i.e., the microscopic
25 rate constant, k_{cat}) as the native endogenous, full-length protein. Those of skill in the art will recognize that k_{cat}/K_m value determines the specificity for competing substrates and is often referred to as the specificity constant. Proteins of this embodiment can have a k_{cat}/K_m value at least 10% of a full-length polypeptide of the present invention as determined using the endogenous substrate of that polypeptide. Optionally, the k_{cat}/K_m
30 value will be at least 20%, 30%, 40%, 50%, and most preferably at least 60%, 70%, 80%, 90%, or 95% the k_{cat}/K_m value of the full-length polypeptide of the present invention. Determination of k_{cat} , K_m , and k_{cat}/K_m can be determined by any number of means well known to those of skill in the art. For example, the initial rates (i.e., the first 5% or less of

the reaction) can be determined using rapid mixing and sampling techniques (e.g., continuous-flow, stopped-flow, or rapid quenching techniques), flash photolysis, or relaxation methods (e.g., temperature jumps) in conjunction with such exemplary methods of measuring as spectrophotometry, spectrofluorimetry, nuclear magnetic resonance, or radioactive procedures. Kinetic values are conveniently obtained using a Lineweaver-Burk or Eadie-Hofstee plot.

F. Polynucleotides Complementary to the Polynucleotides of (A)-(E)

As indicated in (f), above, the present invention provides isolated nucleic acids comprising polynucleotides complementary to the polynucleotides of paragraphs A-E, above. As those of skill in the art will recognize, complementary sequences base-pair throughout the entirety of their length with the polynucleotides of sections (A)-(E) (i.e., have 100% sequence identity over their entire length). Complementary bases associate through hydrogen bonding in double stranded nucleic acids. For example, the following base pairs are complementary: guanine and cytosine; adenine and thymine; and adenine and uracil.

G. Polynucleotides Which are Subsequences of the Polynucleotides of (A)-(F)

As indicated in (g), above, the present invention provides isolated nucleic acids comprising polynucleotides which comprise at least 15 contiguous bases from the polynucleotides of sections (A) through (F) as discussed above. The length of the polynucleotide is given as an integer selected from the group consisting of from at least 15 to the length of the nucleic acid sequence from which the polynucleotide is a subsequence of. Thus, for example, polynucleotides of the present invention are inclusive of polynucleotides comprising at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 contiguous nucleotides in length from the polynucleotides of (A)-(F). Optionally, the number of such subsequences encoded by a polynucleotide of the instant embodiment can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5. The subsequences can be separated by any integer of nucleotides from 1 to the number of nucleotides in the sequence such as at least 5, 10, 15, 25, 50, 100, or 200 nucleotides.

The subsequences of the present invention can comprise structural characteristics of the sequence from which it is derived. Alternatively, the subsequences can lack certain

structural characteristics of the larger sequence from which it is derived such as a poly (A) tail. Optionally, a subsequence from a polynucleotide encoding a polypeptide having at least one linear epitope in common with a prototype polypeptide sequence as provided in (a), above, may encode an epitope in common with the prototype sequence. Alternatively, 5 the subsequence may not encode an epitope in common with the prototype sequence but can be used to isolate the larger sequence by, for example, nucleic acid hybridization with the sequence from which it's derived. Subsequences can be used to modulate or detect gene expression by introducing into the subsequences compounds which bind, intercalate, cleave and/or crosslink to nucleic acids. Exemplary compounds include acridine, psoralen, 10 phenanthroline, naphthoquinone, daunomycin or chloroethylaminoaryl conjugates.

Construction of Nucleic Acids

The isolated nucleic acids of the present invention can be made using (a) standard recombinant methods, (b) synthetic techniques, or combinations thereof. In some 15 embodiments, the polynucleotides of the present invention will be cloned, amplified, or otherwise constructed from a monocot. In preferred embodiments the monocot is *Zea mays*.

The nucleic acids may conveniently comprise sequences in addition to a polynucleotide of the present invention. For example, a multi-cloning site comprising one 20 or more endonuclease restriction sites may be inserted into the nucleic acid to aid in isolation of the polynucleotide. Also, translatable sequences may be inserted to aid in the isolation of the translated polynucleotide of the present invention. For example, a hexahistidine marker sequence provides a convenient means to purify the proteins of the present invention. A polynucleotide of the present invention can be attached to a vector, 25 adapter, or linker for cloning and/or expression of a polynucleotide of the present invention. Additional sequences may be added to such cloning and/or expression sequences to optimize their function in cloning and/or expression, to aid in isolation of the polynucleotide, or to improve the introduction of the polynucleotide into a cell. Typically, the length of a nucleic acid of the present invention less the length of its polynucleotide of 30 the present invention is less than 20 kilobase pairs, often less than 15 kb, and frequently less than 10 kb. Use of cloning vectors, expression vectors, adapters, and linkers is well known and extensively described in the art. For a description of various nucleic acids see,

for example, Stratagene Cloning Systems, Catalogs 1995, 1996, 1997 (La Jolla, CA); and, Amersham Life Sciences, Inc, Catalog '97 (Arlington Heights, IL).

A. Recombinant Methods for Constructing Nucleic Acids

The isolated nucleic acid compositions of this invention, such as RNA, cDNA,
5 genomic DNA, or a hybrid thereof, can be obtained from plant biological sources using any number of cloning methodologies known to those of skill in the art. In some embodiments, oligonucleotide probes which selectively hybridize, under stringent conditions, to the polynucleotides of the present invention are used to identify the desired sequence in a cDNA or genomic DNA library. While isolation of RNA, and construction of cDNA and
10 genomic libraries is well known to those of ordinary skill in the art, the following highlights some of the methods employed.

A1. mRNA Isolation and Purification

Total RNA from plant cells comprises such nucleic acids as mitochondrial RNA,
15 chloroplastic RNA, rRNA, tRNA, hnRNA and mRNA. Total RNA preparation typically involves lysis of cells and removal of organelles and proteins, followed by precipitation of nucleic acids. Extraction of total RNA from plant cells can be accomplished by a variety of means. Frequently, extraction buffers include a strong detergent such as SDS and an organic denaturant such as guanidinium isothiocyanate, guanidine hydrochloride or phenol.
20 Following total RNA isolation, poly(A)⁺ mRNA is typically purified from the remainder RNA using oligo(dT) cellulose. Exemplary total RNA and mRNA isolation protocols are described in *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997); and, *Current Protocols in Molecular Biology*, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995). Total RNA and mRNA isolation
25 kits are commercially available from vendors such as Stratagene (La Jolla, CA), Clontech (Palo Alto, CA), Pharmacia (Piscataway, NJ), and 5'-3' (Paoli Inc., PA). See also, U.S. Patent Nos. 5,614,391; and, 5,459,253. The mRNA can be fractionated into populations with size ranges of about 0.5, 1.0, 1.5, 2.0, 2.5 or 3.0 kb. The cDNA synthesized for each of these fractions can be size selected to the same size range as its mRNA prior to vector
30 insertion. This method helps eliminate truncated cDNA formed by incompletely reverse transcribed mRNA.

A2. Construction of a cDNA Library

Construction of a cDNA library generally entails five steps. First, first strand cDNA synthesis is initiated from a poly(A)⁺ mRNA template using a poly(dT) primer or random hexanucleotides. Second, the resultant RNA-DNA hybrid is converted into double stranded cDNA, typically by reaction with a combination of RNase H and DNA polymerase I (or Klenow fragment). Third, the termini of the double stranded cDNA are ligated to adaptors. Ligation of the adaptors can produce cohesive ends for cloning. Fourth, size selection of the double stranded cDNA eliminates excess adaptors and primer fragments, and eliminates partial cDNA molecules due to degradation of mRNAs or the failure of reverse transcriptase to synthesize complete first strands. Fifth, the cDNAs are ligated into cloning vectors and packaged. cDNA synthesis protocols are well known to the skilled artisan and are described in such standard references as: *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997); and, *Current Protocols in Molecular Biology*, Ausubel, et al., Eds., Greene Publishing and Wiley-Interscience, New York (1995). cDNA synthesis kits are available from a variety of commercial vendors such as Stratagene or Pharmacia.

A number of cDNA synthesis protocols have been described which provide substantially pure full-length cDNA libraries. Substantially pure full-length cDNA libraries are constructed to comprise at least 90%, and more preferably at least 93% or 95% full-length inserts amongst clones containing inserts. The length of insert in such libraries can be from 0 to 8, 9, 10, 11, 12, 13, or more kilobase pairs. Vectors to accommodate inserts of these sizes are known in the art and available commercially. See, e.g., Stratagene's lambda ZAP Express (cDNA cloning vector with 0 to 12 kb cloning capacity).

An exemplary method of constructing a greater than 95% pure full-length cDNA library is described by Carninci et al., *Genomics*, 37:327-336 (1996). In that protocol, the cap-structure of eukaryotic mRNA is chemically labeled with biotin. By using streptavidin-coated magnetic beads, only the full-length first-strand cDNA/mRNA hybrids are selectively recovered after RNase I treatment. The method provides a high yield library with an unbiased representation of the starting mRNA population. Other methods for producing full-length libraries are known in the art. See, e.g., Edery et al., *Mol. Cell Biol.*, 15(6):3363-3371 (1995); and, PCT Application WO 96/34981.

A3. Normalized or Subtracted cDNA Libraries

A non-normalized cDNA library represents the mRNA population of the tissue it was made from. Since unique clones are out-numbered by clones derived from highly expressed genes their isolation can be laborious. Normalization of a cDNA library is the process of creating a library in which each clone is more equally represented.

A number of approaches to normalize cDNA libraries are known in the art. One approach is based on hybridization to genomic DNA. The frequency of each hybridized cDNA in the resulting normalized library would be proportional to that of each corresponding gene in the genomic DNA. Another approach is based on kinetics. If cDNA reannealing follows second-order kinetics, rarer species anneal less rapidly and the remaining single-stranded fraction of cDNA becomes progressively more normalized during the course of the hybridization. Specific loss of any species of cDNA, regardless of its abundance, does not occur at any Cot value. Construction of normalized libraries is described in Ko, *Nucl. Acids. Res.*, 18(19):5705-5711 (1990); Patanjali *et al.*, *Proc. Natl. Acad. U.S.A.*, 88:1943-1947 (1991); U.S. Patents 5,482,685, and 5,637,685. In an exemplary method described by Soares *et al.*, normalization resulted in reduction of the abundance of clones from a range of four orders of magnitude to a narrow range of only 1 order of magnitude. *Proc. Natl. Acad. Sci. USA*, 91:9228-9232 (1994).

Subtracted cDNA libraries are another means to increase the proportion of less abundant cDNA species. In this procedure, cDNA prepared from one pool of mRNA is depleted of sequences present in a second pool of mRNA by hybridization. The cDNA:mRNA hybrids are removed and the remaining un-hybridized cDNA pool is enriched for sequences unique to that pool. See, Foote *et al.* in, *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997); Kho and Zarbl, *Technique*, 3(2):58-63 (1991); Sive and St. John, *Nucl. Acids Res.*, 16(22):10937 (1988); *Current Protocols in Molecular Biology*, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995); and, Swaroop *et al.*, *Nucl. Acids Res.*, 19(8):1954 (1991). cDNA subtraction kits are commercially available. See, e.g., PCR-Select (Clontech, Palo Alto, CA).

A4. Construction of a Genomic Library

To construct genomic libraries, large segments of genomic DNA are generated by fragmentation, e.g. using restriction endonucleases. and are ligated with vector DNA to

form concatemers that can be packaged into the appropriate vector. Methodologies to accomplish these ends, and sequencing methods to verify the sequence of nucleic acids are well known in the art. Examples of appropriate molecular biological techniques and instructions sufficient to direct persons of skill through many construction, cloning, and screening methodologies are found in Sambrook, *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Vols. 1-3 (1989), Methods in Enzymology, Vol. 152: *Guide to Molecular Cloning Techniques*, Berger and Kimmel, Eds., San Diego: Academic Press, Inc. (1987), *Current Protocols in Molecular Biology*, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995); *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997). Kits for construction of genomic libraries are also commercially available.

A5. Nucleic Acid Screening and Isolation Methods

The cDNA or genomic library can be screened using a probe based upon the sequence of a polynucleotide of the present invention such as those disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species. Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to occur. The degree of stringency can be controlled by temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide. For example, the stringency of hybridization is conveniently varied by changing the polarity of the reactant solution through manipulation of the concentration of formamide within the range of 0% to 50%. The degree of complementarity (sequence identity) required for detectable binding will vary in accordance with the stringency of the hybridization medium and/or wash medium. The degree of complementarity will optimally be 100 percent; however, it should be understood that minor sequence variations in the probes and primers may be compensated for by reducing the stringency of the hybridization and/or wash medium.

The nucleic acids of interest can also be amplified from nucleic acid samples using amplification techniques. For instance, polymerase chain reaction (PCR) technology can be used to amplify the sequences of polynucleotides of the present invention and related

genes directly from genomic DNA or cDNA libraries. PCR and other *in vitro* amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes. Examples of techniques sufficient to direct persons of skill through *in vitro* amplification methods are found in Berger, Sambrook, and Ausubel, as well as Mullis *et al.*, U.S. Patent No. 4,683,202 (1987); and, *PCR Protocols A Guide to Methods and Applications*, Innis *et al.*, Eds., Academic Press Inc., San Diego, CA (1990). Commercially available kits for genomic PCR amplification are known in the art. See, e.g., Advantage-GC Genomic PCR Kit (Clontech). The T4 gene 32 protein (Boehringer Mannheim) can be used to improve yield of long PCR products.

PCR-based screening methods have also been described. Wilfinger *et al.* describe a PCR-based method in which the longest cDNA is identified in the first step so that incomplete clones can be eliminated from study. *BioTechniques*, 22(3): 481-486 (1997). In that method, a primer pair is synthesized with one primer annealing to the 5' end of the sense strand of the desired cDNA and the other primer to the vector. Clones are pooled to allow large-scale screening. By this procedure, the longest possible clone is identified amongst candidate clones. Further, the PCR product is used solely as a diagnostic for the presence of the desired cDNA and does not utilize the PCR product itself. Such methods are particularly effective in combination with a full-length cDNA construction methodology, above.

B. Synthetic Methods for Constructing Nucleic Acids

The isolated nucleic acids of the present invention can also be prepared by direct chemical synthesis by methods such as the phosphotriester method of Narang *et al.*, *Meth. Enzymol.* 68: 90-99 (1979); the phosphodiester method of Brown *et al.*, *Meth. Enzymol.* 68: 109-151 (1979); the diethylphosphoramidite method of Beaucage *et al.*, *Tetra. Lett.* 22: 1859-1862 (1981); the solid phase phosphoramidite triester method described by Beaucage and Caruthers, *Tetra. Letts.* 22(20): 1859-1862 (1981), e.g., using an automated synthesizer, e.g., as described in Needham-VanDevanter *et al.*, *Nucleic Acids Res.*, 12: 6159-6168 (1984); and, the solid support method of U.S. Patent No. 4,458,066. Chemical synthesis generally produces a single stranded oligonucleotide. This may be converted into double stranded DNA by hybridization with a complementary sequence, or by

polymerization with a DNA polymerase using the single strand as a template. One of skill will recognize that while chemical synthesis of DNA is best employed for sequences of about 100 bases or less, longer sequences may be obtained by the ligation of shorter sequences.

5

Recombinant Expression Cassettes

The present invention further provides recombinant expression cassettes comprising a nucleic acid of the present invention. A nucleic acid sequence coding for the desired polypeptide of the present invention, for example a cDNA or a genomic sequence encoding a full length polypeptide of the present invention, can be used to construct a recombinant expression cassette which can be introduced into the desired host cell. A recombinant expression cassette will typically comprise a polynucleotide of the present invention operably linked to transcriptional initiation regulatory sequences which will direct the transcription of the polynucleotide in the intended host cell, such as tissues of a transformed plant.

For example, plant expression vectors may include (1) a cloned plant gene under the transcriptional control of 5' and 3' regulatory sequences and (2) a dominant selectable marker. Such plant expression vectors may also contain, if desired, a promoter regulatory region (e.g., one conferring inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific/selective expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

A plant promoter fragment can be employed which will direct expression of a polynucleotide of the present invention in all tissues of a regenerated plant. Such promoters are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*, the ubiquitin 1 promoter, the Smas promoter, the cinnamyl alcohol dehydrogenase promoter (U.S. Patent No. 5,683,439), the *Nos* promoter, the pEmu promoter, the rubisco promoter, the GRP1-8 promoter, and other transcription initiation regions from various plant genes known to those of skill. One exemplary promoter is the

ubiquitin promoter, which can be used to drive expression of the present invention in maize embryos or embryogenic callus.

Alternatively, the plant promoter can direct expression of a polynucleotide of the present invention in a specific tissue or may be otherwise under more precise
5 environmental or developmental control. Such promoters are referred to here as "inducible" promoters. Environmental conditions that may effect transcription by inducible promoters include pathogen attack, anaerobic conditions, or the presence of light. Examples of inducible promoters are the Adh1 promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, and the PPDK promoter
10 which is inducible by light.

Examples of promoters under developmental control include promoters that initiate transcription only, or preferentially, in certain tissues, such as leaves, roots, fruit, seeds, or flowers. Exemplary promoters include the anther specific promoter 5126 (U.S. Patent Nos. 5,689,049 and 5,689,051), glob-1 promoter, and gamma-zein promoter. The operation of a
15 promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

Both heterologous and non-heterologous (i.e., endogenous) promoters can be employed to direct expression of the nucleic acids of the present invention. These promoters can also be used, for example, in recombinant expression cassettes to drive
20 expression of antisense nucleic acids to reduce, increase, or alter concentration and/or composition of the proteins of the present invention in a desired tissue. Thus, in some embodiments, the nucleic acid construct will comprise a promoter functional in a plant cell, such as in *Zea mays*, operably linked to a polynucleotide of the present invention. Promoters useful in these embodiments include the endogenous promoters driving
25 expression of a polypeptide of the present invention.

In some embodiments, isolated nucleic acids which serve as promoter or enhancer elements can be introduced in the appropriate position (generally upstream) of a non-heterologous form of a polynucleotide of the present invention so as to up or down regulate expression of a polynucleotide of the present invention. For example, endogenous
30 promoters can be altered *in vivo* by mutation, deletion, and/or substitution (see, Kmiec, U.S. Patent 5,565,350; Zarling *et al.*, PCT/US93/03868), or isolated promoters can be introduced into a plant cell in the proper orientation and distance from a gene of the present invention so as to control the expression of the gene. Gene expression can be modulated

under conditions suitable for plant growth so as to alter the total concentration and/or alter the composition of the polypeptides of the present invention in plant cell. Thus, the present invention provides compositions, and methods for making, heterologous promoters and/or enhancers operably linked to a native, endogenous (i.e., non-heterologous) form of a
5 polynucleotide of the present invention.

Methods for identifying promoters with a particular expression pattern, in terms of, e.g., tissue type, cell type, stage of development, and/or environmental conditions, are well known in the art. See, e.g., *The Maize Handbook*, Chapters 114-115, Freeling and Walbot, Eds., Springer, New York (1994); *Corn and Corn Improvement*, 3rd edition, Chapter 6,
10 Sprague and Dudley, Eds., American Society of Agronomy, Madison, Wisconsin (1988). A typical step in promoter isolation methods is identification of gene products that are expressed with some degree of specificity in the target tissue. Amongst the range of methodologies are: differential hybridization to cDNA libraries; subtractive hybridization; differential display; differential 2-D protein gel electrophoresis; DNA probe arrays; and
15 isolation of proteins known to be expressed with some specificity in the target tissue. Such methods are well known to those of skill in the art. Commercially available products for identifying promoters are known in the art such as Clontech's (Palo Alto, CA) Universal GenomeWalker Kit.

For the protein-based methods, it is helpful to obtain the amino acid sequence for at
20 least a portion of the identified protein, and then to use the protein sequence as the basis for preparing a nucleic acid that can be used as a probe to identify either genomic DNA directly, or preferably, to identify a cDNA clone from a library prepared from the target tissue. Once such a cDNA clone has been identified, that sequence can be used to identify the sequence at the 5' end of the transcript of the indicated gene. For differential
25 hybridization, subtractive hybridization and differential display, the nucleic acid sequence identified as enriched in the target tissue is used to identify the sequence at the 5' end of the transcript of the indicated gene. Once such sequences are identified, starting either from protein sequences or nucleic acid sequences, any of these sequences identified as being from the gene transcript can be used to screen a genomic library prepared from the
30 target organism. Methods for identifying and confirming the transcriptional start site are well known in the art.

In the process of isolating promoters expressed under particular environmental conditions or stresses, or in specific tissues, or at particular developmental stages, a

number of genes are identified that are expressed under the desired circumstances, in the desired tissue, or at the desired stage. Further analysis will reveal expression of each particular gene in one or more other tissues of the plant. One can identify a promoter with activity in the desired tissue or condition but that does not have activity in any other
5 common tissue.

To identify the promoter sequence, the 5' portions of the clones described here are analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually an AT-rich stretch of 5-10 bp located approximately 20 to 40 base pairs upstream
10 of the transcription start site. Identification of the TATA box is well known in the art. For example, one way to predict the location of this element is to identify the transcription start site using standard RNA-mapping techniques such as primer extension, S1 analysis, and/or RNase protection. To confirm the presence of the AT-rich sequence, a structure-function analysis can be performed involving mutagenesis of the putative region and quantification
15 of the mutation's effect on expression of a linked downstream reporter gene. See, e.g., *The Maize Handbook*, Chapter 114, Freeling and Walbot, Eds., Springer, New York, (1994).

In plants, further upstream from the TATA box, at positions -80 to -100, there is typically a promoter element (i.e., the CAAT box) with a series of adenines surrounding the trinucleotide G (or T) N G. J. Messing *et al.*, in *Genetic Engineering in Plants*,
20 Kosage, Meredith and Hollaender, Eds., pp. 221-227 (1983). In maize, there is no well conserved CAAT box but there are several short, conserved protein-binding motifs upstream of the TATA box. These include motifs for the trans-acting transcription factors involved in light regulation, anaerobic induction, hormonal regulation, or anthocyanin biosynthesis, as appropriate for each gene.

Once promoter and/or gene sequences are known, a region of suitable size is selected from the genomic DNA that is 5' to the transcriptional start, or the translational start site, and such sequences are then linked to a coding sequence. If the transcriptional start site is used as the point of fusion, any of a number of possible 5' untranslated regions can be used in between the transcriptional start site and the partial coding sequence. If the
30 translational start site at the 3' end of the specific promoter is used, then it is linked directly to the methionine start codon of a coding sequence.

If polypeptide expression is desired, it is generally desirable to include a polyadenylation region at the 3'-end of a polynucleotide coding region. The

polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA. The 3' end sequence to be added can be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or less preferably from any other eukaryotic gene.

5 An intron sequence can be added to the 5' untranslated region or the coding sequence of the partial coding sequence to increase the amount of the mature message that accumulates in the cytosol. Inclusion of a spliceable intron in the transcription unit in both plant and animal expression constructs has been shown to increase gene expression at both the mRNA and protein levels up to 1000-fold. Buchman and Berg, *Mol. Cell Biol.* 8: 4395-
10 4405 (1988); Callis *et al.*, *Genes Dev.* 1: 1183-1200 (1987). Such intron enhancement of gene expression is typically greatest when placed near the 5' end of the transcription unit. Use of maize introns Adh1-S intron 1, 2, and 6, the Bronze-1 intron are known in the art. See generally, *The Maize Handbook*, Chapter 116, Freeling and Walbot, Eds., Springer, New York (1994).

15 The vector comprising the sequences from a polynucleotide of the present invention will typically comprise a marker gene which confers a selectable phenotype on plant cells. Usually, the selectable marker gene will encode antibiotic resistance, with suitable genes including genes coding for resistance to the antibiotic spectinomycin (e.g., the *aada* gene), the streptomycin phosphotransferase (SPT) gene coding for streptomycin
20 resistance, the neomycin phosphotransferase (NPTII) gene encoding kanamycin or geneticin resistance, the hygromycin phosphotransferase (HPT) gene coding for hygromycin resistance, genes coding for resistance to herbicides which act to inhibit the action of acetolactate synthase (ALS), in particular the sulfonylurea-type herbicides (e.g., the acetolactate synthase (ALS) gene containing mutations leading to such resistance in
25 particular the S4 and/or Hra mutations), genes coding for resistance to herbicides which act to inhibit action of glutamine synthase, such as phosphinothricin or basta (e.g., the *bar* gene), or other such genes known in the art. The *bar* gene encodes resistance to the herbicide basta, the *nptII* gene encodes resistance to the antibiotics kanamycin and geneticin, and the ALS gene encodes resistance to the herbicide chlorsulfuron.

30 Typical vectors useful for expression of genes in higher plants are well known in the art and include vectors derived from the tumor-inducing (Ti) plasmid of *Agrobacterium tumefaciens* described by Rogers *et al.*, *Meth. In Enzymol.*, 153:253-277 (1987). These vectors are plant integrating vectors in that on transformation, the vectors integrate a

portion of vector DNA into the genome of the host plant. Exemplary *A. tumefaciens* vectors useful herein are plasmids pKYLX6 and pKYLX7 of Schardl *et al.*, *Gene*, 61:1-11 (1987) and Berger *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 86:8402-8406 (1989). Another useful vector herein is plasmid pBI101.2 that is available from Clontech Laboratories, Inc. 5 (Palo Alto, CA).

A polynucleotide of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable plant characteristics. Antisense technology can be conveniently used to inhibit gene expression 10 in plants. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti-sense strand of RNA will be transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, e.g., Sheehy *et al.*, 15 *Proc. Nat'l. Acad. Sci. (USA)* 85: 8805-8809 (1988); and Hiatt *et al.*, U.S. Patent No. 4,801,340.

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method to 20 modulate expression of endogenous genes see, Napoli *et al.*, *The Plant Cell* 2: 279-289 (1990) and U.S. Patent No. 5,034,323.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of plant genes. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby 25 functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described in Haseloff *et al.*, *Nature* 334: 585- 30 591 (1988).

A variety of cross-linking agents, alkylating agents and radical generating species as pendant groups on polynucleotides of the present invention can be used to bind, label, detect, and/or cleave nucleic acids. For example, Vlassov, V. V., *et al.*, *Nucleic Acids Res*

(1986) 14:4065-4076, describe covalent bonding of a single-stranded DNA fragment with alkylating derivatives of nucleotides complementary to target sequences. A report of similar work by the same group is that by Knorre, D. G., *et al.*, *Biochimie* (1985) 67:785-789. Iverson and Dervan also showed sequence-specific cleavage of single-stranded DNA mediated by incorporation of a modified nucleotide which was capable of activating cleavage (*J Am Chem Soc* (1987) 109:1241-1243). Meyer, R. B., *et al.*, *J Am Chem Soc* (1989) 111:8517-8519, effect covalent crosslinking to a target nucleotide using an alkylating agent complementary to the single-stranded target nucleotide sequence. A photoactivated crosslinking to single-stranded oligonucleotides mediated by psoralen was disclosed by Lee, B. L., *et al.*, *Biochemistry* (1988) 27:3197-3203. Use of crosslinking in triple-helix forming probes was also disclosed by Home, *et al.*, *J Am Chem Soc* (1990) 112:2435-2437. Use of N4, N4-ethanocytosine as an alkylating agent to crosslink to single-stranded oligonucleotides has also been described by Webb and Matteucci, *J Am Chem Soc* (1986) 108:2764-2765; *Nucleic Acids Res* (1986) 14:7661-7674; Feteritz *et al.*, *J. Am. Chem. Soc.* 113:4000 (1991). Various compounds to bind, detect, label, and/or cleave nucleic acids are known in the art. See, for example, U.S. Patent Nos. 5,543,507; 5,672,593; 5,484,908; 5,256,648; and, 5,681,941.

Proteins

The isolated proteins of the present invention comprise a polypeptide having at least 10 amino acids encoded by any one of the polynucleotides of the present invention as discussed more fully, above, or polypeptides which are conservatively modified variants thereof. The proteins of the present invention or variants thereof can comprise any number of contiguous amino acid residues from a polypeptide of the present invention, wherein that number is selected from the group of integers consisting of from 10 to the number of residues in a full-length polypeptide of the present invention. Optionally, this subsequence of contiguous amino acids is at least 15, 20, 25, 30, 35, or 40 amino acids in length, often at least 50, 60, 70, 80, or 90 amino acids in length. Further, the number of such subsequences can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5.

The present invention further provides a protein comprising a polypeptide having a specified sequence identity with a polypeptide of the present invention. The percentage of sequence identity is an integer selected from the group consisting of from 50 to 99.

Exemplary sequence identity values include 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99%. Sequence identity can be determined using, for example, the GAP or BLAST algorithms.

5 As those of skill will appreciate, the present invention includes catalytically active polypeptides of the present invention (i.e., enzymes). Catalytically active polypeptides have a specific activity of at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% that of the native (non-synthetic), endogenous polypeptide. Further, the substrate specificity (k_{cat}/K_m) is optionally
10 substantially similar to the native (non-synthetic), endogenous polypeptide. Typically, the K_m will be at least 30%, 40%, or 50%, that of the native (non-synthetic), endogenous polypeptide; and more preferably at least 60%, 70%, 80%, or 90%. Methods of assaying and quantifying measures of enzymatic activity and substrate specificity (k_{cat}/K_m), are well known to those of skill in the art.

15 Generally, the proteins of the present invention will, when presented as an immunogen, elicit production of an antibody specifically reactive to a polypeptide of the present invention. Further, the proteins of the present invention will not bind to antisera raised against a polypeptide of the present invention which has been fully immunosorbed with the same polypeptide. Immunoassays for determining binding are well known to
20 those of skill in the art. A preferred immunoassay is a competitive immunoassay as discussed, *infra*. Thus, the proteins of the present invention can be employed as immunogens for constructing antibodies immunoreactive to a protein of the present invention for such exemplary utilities as immunoassays or protein purification techniques.

25 Expression of Proteins in Host Cells

 Using the nucleic acids of the present invention, one may express a protein of the present invention in a recombinantly engineered cell such as bacteria, yeast, insect, mammalian, or preferably plant cells. The cells produce the protein in a non-natural condition (e.g., in quantity, composition, location, and/or time), because they have been
30 genetically altered through human intervention to do so.

 It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of a nucleic acid encoding a protein of the

present invention. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made.

In brief summary, the expression of isolated nucleic acids encoding a protein of the present invention will typically be achieved by operably linking, for example, the DNA or cDNA to a promoter (which is either constitutive or regulatable), followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the DNA encoding a protein of the present invention. To obtain high level expression of a cloned gene, it is desirable to construct expression vectors which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. One of skill would recognize that modifications can be made to a protein of the present invention without diminishing its biological activity. Some modifications may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located purification sequences. Restriction sites or termination codons can also be introduced.

20

A. Expression in Prokaryotes

Prokaryotic cells may be used as hosts for expression. Prokaryotes most frequently are represented by various strains of *E. coli*; however, other microbial strains may also be used. Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al., *Nature* 198:1056 (1977)), the tryptophan (trp) promoter system (Goeddel et al., *Nucleic Acids Res.* 8:4057 (1980)) and the lambda derived P L promoter and N-gene ribosome binding site (Shimatake et al., *Nature* 292:128 (1981)). The inclusion of selection markers in DNA vectors transfected in *E. coli* is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol.

30

The vector is selected to allow introduction into the appropriate host cell. Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with naked phage vector DNA. If a plasmid vector is used, the bacterial cells are transfected with the plasmid vector DNA. Expression systems for expressing a protein of the present invention are available using *Bacillus sp.* and *Salmonella* (Palva, *et al.*, *Gene* 22: 229-235 (1983); Mosbach, *et al.*, *Nature* 302: 543-545 (1983)).

B. Expression in Eukaryotes

10 A variety of eukaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells, are known to those of skill in the art. As explained briefly below, a polynucleotide of the present invention can be expressed in these eukaryotic systems. In some embodiments, transformed/transfected plant cells, as discussed *infra*, are employed as expression systems for production of the proteins of the instant invention.

15 Synthesis of heterologous proteins in yeast is well known. Sherman, F., *et al.*, *Methods in Yeast Genetics*, Cold Spring Harbor Laboratory (1982) is a well recognized work describing the various methods available to produce the protein in yeast. Two widely utilized yeast for production of eukaryotic proteins are *Saccharomyces cerevisiae* and *Pichia pastoris*. Vectors, strains, and protocols for expression in *Saccharomyces* and
20 *Pichia* are known in the art and available from commercial suppliers (e.g., Invitrogen). Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphoglycerate kinase or alcohol oxidase, and an origin of replication, termination sequences and the like as desired.

A protein of the present invention, once expressed, can be isolated from yeast by
25 lysing the cells and applying standard protein isolation techniques to the lysates. The monitoring of the purification process can be accomplished by using Western blot techniques or radioimmunoassay or other standard immunoassay techniques.

The sequences encoding proteins of the present invention can also be ligated to various expression vectors for use in transfecting cell cultures of, for instance, mammalian,
30 insect, or plant origin. Illustrative of cell cultures useful for the production of the peptides are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. A number of suitable host cell lines capable of expressing intact proteins have been developed in the art, and include

the HEK293, BHK21, and CHO cell lines. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMV promoter, a HSV *tk* promoter or *pgk* (phosphoglycerate kinase) promoter), an enhancer (Queen *et al.*, *Immunol. Rev.* 89: 49 (1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., an SV40 large T Ag poly A addition site), and transcriptional terminator sequences. Other animal cells useful for production of proteins of the present invention are available, for instance, from the American Type Culture Collection.

Appropriate vectors for expressing proteins of the present invention in insect cells are usually derived from the SF9 baculovirus. Suitable insect cell lines include mosquito larvae, silkworm, armyworm, moth and *Drosophila* cell lines such as a Schneider cell line (See, Schneider, *J. Embryol. Exp. Morphol.* 27: 353-365 (1987)).

As with yeast, when higher animal or plant host cells are employed, polyadenylation or transcription terminator sequences are typically incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, *et al.*, *J. Virol.* 45: 773-781 (1983)). Additionally, gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. Saveria-Campo, M., Bovine Papilloma Virus DNA a Eukaryotic Cloning Vector in *DNA Cloning Vol. II a Practical Approach*, D.M. Glover, Ed., IRL Press, Arlington, Virginia pp. 213-238 (1985).

Transfection/Transformation of Cells

The method of transformation/transfection is not critical to the instant invention; various methods of transformation or transfection are currently available. As newer methods are available to transform crops or other host cells they may be directly applied. Accordingly, a wide variety of methods have been developed to insert a DNA sequence into the genome of a host cell to obtain the transcription and/or translation of the sequence to effect phenotypic changes in the organism. Thus, any method which provides for effective transformation/transfection may be employed.

A. Plant Transformation

A DNA sequence coding for the desired polypeptide of the present invention, for example a cDNA or a genomic sequence encoding a full length protein, will be used to construct a recombinant expression cassette which can be introduced into the desired plant.

- 5 Isolated nucleic acids of the present invention can be introduced into plants according to techniques known in the art. Generally, recombinant expression cassettes as described above and suitable for transformation of plant cells are prepared. The isolated nucleic acids of the present invention can then be used for transformation. In this manner, genetically modified plants, plant cells, plant tissue, seed, and the like can be obtained.
- 10 Transformation protocols may vary depending on the type of plant cell, i.e. monocot or dicot, targeted for transformation. Suitable methods of transforming plant cells include microinjection (Crossway *et al.* (1986) *Biotechniques* 4:320-334), electroporation (Riggs *et al.* (1986) *Proc. Natl. Acad. Sci. USA* 83:5602-5606, *Agrobacterium* mediated transformation (see for example, Zhao *et al.* U.S. Patent 5,981,840; Hinchey *et al.* (1988) *Biotechnology* 6:915-921), direct gene transfer (Paszkowski *et al.* (1984) *EMBO J.* 3:2717-2722), and ballistic particle acceleration (see, for example, Sanford *et al.* U.S. Patent 4,945,050; Tomes *et al.* "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment" In Gamborg and Phillips (Eds.) *Plant Cell, Tissue and Organ Culture: Fundamental Methods*, Springer-Verlag, Berlin (1995); and McCabe *et al.* (1988) *Biotechnology* 6:923-926). Also see, Weissinger *et al.* (1988) *Annual Rev. Genet.* 22:421-477; Sanford *et al.* (1987) *Particulate Science and Technology* 5:27-37 (onion); Christou *et al.* (1988) *Plant Physiol.* 87:671-674 (soybean); McCabe *et al.* (1988) *Bio/Technology* 6:923-926 (soybean); Datta *et al.* (1990) *Biotechnology* 8:736-740 (rice); Klein *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:4305-4309 (maize); Klein *et al.* (1988) *Biotechnology* 6:559-563 (maize); Tomes *et al.* "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment" In Gamborg and Phillips (Eds.) *Plant Cell, Tissue and Organ Culture: Fundamental Methods*, Springer-Verlag, Berlin (1995) (maize); Klein *et al.* (1988) *Plant Physiol.* 91:440-444 (maize) Fromm *et al.* (1990) *Biotechnology* 8:833-839 (maize); Hooykaas-Van Slogteren & Hooykaas (1984) *Nature (London)* 311:763-764; Bytebier *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:5345-5349 (Liliaceae); De Wet *et al.* (1985) In *The Experimental Manipulation of Ovule Tissues* ed. G.P. Chapman *et al.* pp. 197-209. Longman, NY (pollen); Kaeppler *et al.* (1990) *Plant Cell Reports* 9:415-418; and Kaeppler *et al.* (1992) *Theor. Appl. Genet.* 84:560-566 (whisker-mediated

transformation); D'Halluin *et al.* (1992) *Plant Cell* 4:1495-1505 (electroporation); LI *et al.* (1993) *Plant Cell Reports* 12:250-255 and Christou and Ford (1995) *Annals of Botany* 75:745-750 (maize via *Agrobacterium tumefaciens*); all of which are herein incorporated by reference.

5 The cells which have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick *et al.* (1986) *Plant Cell Reports*, 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that the subject
10 phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure the desired phenotype or other property has been achieved.

B. Transfection of Prokaryotes, Lower Eukaryotes, and Animal Cells

 Animal and lower eukaryotic (e.g., yeast) host cells are competent or rendered
15 competent for transfection by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextran, electroporation, biolistics, and micro-injection of the DNA directly into the cells. The transfected cells are
20 cultured by means well known in the art. Kuchler, R.J., *Biochemical Methods in Cell Culture and Virology*, Dowden, Hutchinson and Ross, Inc. (1977).

Synthesis of Proteins

 The proteins of the present invention can be constructed using non-cellular
25 synthetic methods. Solid phase synthesis of proteins of less than about 50 amino acids in length may be accomplished by attaching the C-terminal amino acid of the sequence to an insoluble support followed by sequential addition of the remaining amino acids in the sequence. Techniques for solid phase synthesis are described by Barany and Merrifield, Solid-Phase Peptide Synthesis, pp. 3-284 in *The Peptides: Analysis, Synthesis, Biology*.
30 Vol. 2: *Special Methods in Peptide Synthesis, Part A.*; Merrifield, *et al.*, *J. Am. Chem. Soc.* 85: 2149-2156 (1963), and Stewart *et al.*, *Solid Phase Peptide Synthesis*, 2nd ed., Pierce Chem. Co., Rockford, Ill. (1984). Proteins of greater length may be synthesized by condensation of the amino and carboxy termini of shorter fragments. Methods of forming

peptide bonds by activation of a carboxy terminal end (e.g., by the use of the coupling reagent N,N'-dicyclohexylcarbodiimide)) is known to those of skill.

Purification of Proteins

5 The proteins of the present invention may be purified by standard techniques well known to those of skill in the art. Recombinantly produced proteins of the present invention can be directly expressed or expressed as a fusion protein. The recombinant protein is purified by a combination of cell lysis (e.g., sonication, French press) and affinity chromatography. For fusion products, subsequent digestion of the fusion protein with an
10 appropriate proteolytic enzyme releases the desired recombinant protein.

 The proteins of this invention, recombinant or synthetic, may be purified to substantial purity by standard techniques well known in the art, including detergent solubilization, selective precipitation with such substances as ammonium sulfate, column chromatography, immunopurification methods, and others. *See, for instance, R. Scopes,*
15 *Protein Purification: Principles and Practice*, Springer-Verlag: New York (1982);
Deutscher, Guide to Protein Purification, Academic Press (1990). For example, antibodies may be raised to the proteins as described herein. Purification from *E. coli* can be achieved following procedures described in U.S. Patent No. 4,511,503. The protein may then be isolated from cells expressing the protein and further purified by standard
20 protein chemistry techniques as described herein. Detection of the expressed protein is achieved by methods known in the art and include, for example, radioimmunoassays, Western blotting techniques or immunoprecipitation.

Transgenic Plant Regeneration

25 Plants cells transformed with a plant expression vector can be regenerated, e.g., from single cells, callus tissue or leaf discs according to standard plant tissue culture techniques. It is well known in the art that various cells, tissues, and organs from almost any plant can be successfully cultured to regenerate an entire plant. Plant regeneration from cultured protoplasts is described in Evans *et al.*, *Protoplasts Isolation and Culture*,
30 *Handbook of Plant Cell Culture*, Macmillan Publishing Company, New York, pp. 124-176 (1983); and Binding, *Regeneration of Plants, Plant Protoplasts*, CRC Press, Boca Raton, pp. 21-73 (1985).

The regeneration of plants containing the foreign gene introduced by *Agrobacterium* from leaf explants can be achieved as described by Horsch *et al.*, *Science*, 227:1229-1231 (1985). In this procedure, transformants are grown in the presence of a selection agent and in a medium that induces the regeneration of shoots in the plant species
5 being transformed as described by Fraley *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)*, 80:4803 (1983). This procedure typically produces shoots within two to four weeks and these transformant shoots are then transferred to an appropriate root-inducing medium containing the selective agent and an antibiotic to prevent bacterial growth. Transgenic plants of the present invention may be fertile or sterile.

10 Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee *et al.*, *Ann. Rev. of Plant Phys.* 38: 467-486 (1987). The regeneration of plants from either single plant protoplasts or various explants is well known in the art. See, for example, *Methods for Plant Molecular Biology*, A. Weissbach and H. Weissbach, eds., Academic Press, Inc., San
15 Diego, Calif. (1988). This regeneration and growth process includes the steps of selection of transformant cells and shoots, rooting the transformant shoots and growth of the plantlets in soil. For maize cell culture and regeneration see generally, *The Maize Handbook*, Freeling and Walbot, Eds., Springer, New York (1994); *Corn and Corn Improvement*, 3rd edition, Sprague and Dudley Eds., American Society of Agronomy,
20 Madison, Wisconsin (1988).

One of skill will recognize that after the recombinant expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

25 In vegetatively propagated crops, mature transgenic plants can be propagated by the taking of cuttings or by tissue culture techniques to produce multiple identical plants. Selection of desirable transgenics is made and new varieties are obtained and propagated vegetatively for commercial use. In seed propagated crops, mature transgenic plants can be self crossed to produce a homozygous inbred plant. The inbred plant produces seed
30 containing the newly introduced heterologous nucleic acid. These seeds can be grown to produce plants that would produce the selected phenotype.

Parts obtained from the regenerated plant, such as flowers, seeds, leaves, branches, fruit, and the like are included in the invention, provided that these parts comprise cells

comprising the isolated nucleic acid of the present invention. Progeny and variants, and mutants of the regenerated plants are also included within the scope of the invention, provided that these parts comprise the introduced nucleic acid sequences.

Transgenic plants expressing the selectable marker can be screened for
5 transmission of the nucleic acid of the present invention by, for example, standard immunoblot and DNA detection techniques. Transgenic lines are also typically evaluated on levels of expression of the heterologous nucleic acid. Expression at the RNA level can be determined initially to identify and quantitate expression-positive plants. Standard techniques for RNA analysis can be employed and include PCR amplification assays using
10 oligonucleotide primers designed to amplify only the heterologous RNA templates and solution hybridization assays using heterologous nucleic acid-specific probes. The RNA-positive plants can then analyzed for protein expression by Western immunoblot analysis using the specifically reactive antibodies of the present invention. In addition, *in situ* hybridization and immunocytochemistry according to standard protocols can be done using
15 heterologous nucleic acid specific polynucleotide probes and antibodies, respectively, to localize sites of expression within transgenic tissue. Generally, a number of transgenic lines are usually screened for the incorporated nucleic acid to identify and select plants with the most appropriate expression profiles.

A preferred embodiment is a transgenic plant that is homozygous for the added
20 heterologous nucleic acid; i.e., a transgenic plant that contains two added nucleic acid sequences, one gene at the same locus on each chromosome of a chromosome pair. A homozygous transgenic plant can be obtained by sexually mating (selfing) a heterozygous transgenic plant that contains a single added heterologous nucleic acid, germinating some of the seed produced and analyzing the resulting plants produced for altered expression of
25 a polynucleotide of the present invention relative to a control plant (i.e., native, non-transgenic). Back-crossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated.

Modulating Polypeptide Levels and/or Composition

30 The present invention further provides a method for modulating (i.e., increasing or decreasing) the concentration or ratio of the polypeptides of the present invention in a plant or part thereof. Modulation can be effected by increasing or decreasing the concentration and/or the ratio of the polypeptides of the present invention in a plant. The method

comprises introducing into a plant cell with a recombinant expression cassette comprising a polynucleotide of the present invention as described above to obtain a transformed plant cell, culturing the transformed plant cell under plant cell growing conditions, and inducing or repressing expression of a polynucleotide of the present invention in the plant for a time
5 sufficient to modulate concentration and/or the ratios of the polypeptides in the plant or plant part.

In some embodiments, the concentration and/or ratios of polypeptides of the present invention in a plant may be modulated by altering, *in vivo* or *in vitro*, the promoter of a gene to up- or down-regulate gene expression. In some embodiments, the coding
10 regions of native genes of the present invention can be altered via substitution, addition, insertion, or deletion to decrease activity of the encoded enzyme. See, e.g., Kmiec, U.S. Patent 5,565,350; Zarling *et al.*, PCT/US93/03868. And in some embodiments, an isolated nucleic acid (e.g., a vector) comprising a promoter sequence is transfected into a plant cell. Subsequently, a plant cell comprising the promoter operably linked to a polynucleotide of
15 the present invention is selected for by means known to those of skill in the art such as, but not limited to, Southern blot, DNA sequencing, or PCR analysis using primers specific to the promoter and to the gene and detecting amplicons produced therefrom. A plant or plant part altered or modified by the foregoing embodiments is grown under plant forming conditions for a time sufficient to modulate the concentration and/or ratios of polypeptides
20 of the present invention in the plant. Plant forming conditions are well known in the art and discussed briefly, *supra*.

In general, concentration or the ratios of the polypeptides is increased or decreased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% relative to a native control plant, plant part, or cell lacking the aforementioned recombinant expression
25 cassette. Modulation in the present invention may occur during and/or subsequent to growth of the plant to the desired stage of development. Modulating nucleic acid expression temporally and/or in particular tissues can be controlled by employing the appropriate promoter operably linked to a polynucleotide of the present invention in. for example, sense or antisense orientation as discussed in greater detail, *supra*. Induction of
30 expression of a polynucleotide of the present invention can also be controlled by exogenous administration of an effective amount of inducing compound. Inducible promoters and inducing compounds which activate expression from these promoters are

well known in the art. In preferred embodiments, the polypeptides of the present invention are modulated in monocots, particularly maize.

Molecular Markers

5 The present invention provides a method of genotyping a plant comprising a Rad50 polynucleotide of the present invention. Preferably, the plant is a monocot, such as maize or sorghum. Genotyping provides a means of distinguishing homologs of a chromosome pair and can be used to differentiate segregants in a plant population.

 Molecular marker methods can be used for phylogenetic studies, characterizing
10 genetic relationships among crop varieties, identifying crosses or somatic hybrids, localizing chromosomal segments affecting monogenic traits, map based cloning, and the study of quantitative inheritance. See, e.g., *Plant Molecular Biology: A Laboratory Manual*, Chapter 7, Clark, Ed., Springer-Verlag, Berlin (1997). For molecular marker methods, see generally, *The DNA Revolution* by Andrew H. Paterson 1996 (Chapter 2) in:
15 Genome Mapping in Plants (ed. Andrew H. Paterson) by Academic Press/R. G. Landis Company, Austin, Texas, pp.7-21.

 The particular method of genotyping in the present invention may employ any number of molecular marker analytic techniques such as, but not limited to, restriction fragment length polymorphisms (RFLPs). RFLPs are the product of allelic differences
20 between DNA restriction fragments resulting from nucleotide sequence variability. As is well known to those of skill in the art, RFLPs are typically detected by extraction of genomic DNA and digestion with a restriction enzyme. Generally, the resulting fragments are separated according to size and hybridized with a probe; single copy probes are preferred. Restriction fragments from homologous chromosomes are revealed.
25 Differences in fragment size among alleles represent an RFLP. Thus, the present invention further provides a means to follow segregation of Rad50 genes of the present invention as well as chromosomal sequences genetically linked to Rad50 genes using such techniques as RFLP analysis. Linked chromosomal sequences are within 50 centiMorgans (cM), often within 40 or 30 cM, preferably within 20 or 10 cM, more preferably within 5, 3, 2, or 1 cM
30 of a Rad50 gene of the present invention.

 In the present invention, the nucleic acid probes employed for molecular marker mapping of plant nuclear genomes selectively hybridize, under selective hybridization conditions, to a gene encoding a Rad50 polynucleotide. In preferred embodiments, the

probes are selected from polynucleotides of the present invention. Typically, these probes are cDNA probes or restriction-enzyme treated (e.g., *Pst* I) genomic clones. In the present invention probes can be made from the polynucleotide of SEQ ID NO: 1. The length of the probes is discussed in greater detail, *supra*, but are typically at least 15 bases in length, more preferably at least 20, 25, 30, 35, 40, or 50 bases in length. Generally, however, the probes are less than about 1 kilobase in length. Preferably, the probes are single copy probes that hybridize to a unique locus in a haploid chromosome complement. Some exemplary restriction enzymes employed in RFLP mapping are *Eco*RI, *Eco*Rv, and *Sst*I. As used herein the term "restriction enzyme" includes reference to a composition that recognizes and, alone or in conjunction with another composition, cleaves at a specific nucleotide sequence.

The method of detecting an RFLP comprises the steps of (a) digesting genomic DNA of a plant with a restriction enzyme; (b) hybridizing a nucleic acid probe, under selective hybridization conditions, to a sequence of a polynucleotide of the present of said genomic DNA; (c) detecting therefrom a RFLP.

Other methods of differentiating polymorphic (allelic) variants of polynucleotides of the present invention can be had by utilizing molecular marker techniques well known to those of skill in the art including such techniques as: 1) single stranded conformation analysis (SSCA); 2) denaturing gradient gel electrophoresis (DGGE); 3) RNase protection assays; 4) allele-specific oligonucleotides (ASOs); 5) the use of proteins which recognize nucleotide mismatches, such as the *E. coli* mutS protein; and 6) allele-specific PCR. Other approaches based on the detection of mismatches between the two complementary DNA strands include clamped denaturing gel electrophoresis (CDGE); heteroduplex analysis (HA); and chemical mismatch cleavage (CMC). Thus, the present invention further provides a method of genotyping comprising the steps of contacting, under stringent hybridization conditions, a sample suspected of comprising a Rad50 polynucleotide with a nucleic acid probe. Generally, the sample is a plant sample; preferably, a sample suspected of comprising a maize polynucleotide of the present invention (e.g., gene, mRNA). The nucleic acid probe selectively hybridizes, under stringent conditions, to a subsequence of a Rad50 polynucleotide comprising a polymorphic marker. Selective hybridization of the nucleic acid probe to the polymorphic marker nucleic acid sequence yields a hybridization complex. Detection of the hybridization complex indicates the presence of that

polymorphic marker in the sample. In preferred embodiments, the nucleic acid probe comprises a polynucleotide of the present invention.

UTRs and Codon Preference

5 In general, translational efficiency has been found to be regulated by specific sequence elements in the 5' non-coding or untranslated region (5' UTR) of the RNA. Positive sequence motifs include translational initiation consensus sequences (Kozak, *Nucleic Acids Res.* 15:8125 (1987)) and the 7-methylguanosine cap structure (Drummond *et al.*, *Nucleic Acids Res.* 13:7375 (1985)). Negative elements include stable
10 intramolecular 5' UTR stem-loop structures (Muesing *et al.*, *Cell* 48:691 (1987)) and AUG sequences or short open reading frames preceded by an appropriate AUG in the 5' UTR (Kozak, *supra*, Rao *et al.*, *Mol. and Cell. Biol.* 8:284 (1988)). Accordingly, the present invention provides 5' and/or 3' UTR regions for modulation of translation of heterologous coding sequences.

15 Further, the polypeptide-encoding segments of the polynucleotides of the present invention can be modified to alter codon usage. Altered codon usage can be employed to alter translational efficiency and/or to optimize the coding sequence for expression in a desired host such as to optimize the codon usage in a heterologous sequence for expression in maize. Codon usage in the coding regions of the polynucleotides of the present
20 invention can be analyzed statistically using commercially available software packages such as "Codon Preference" available from the University of Wisconsin Genetics Computer Group (see Devereaux *et al.*, *Nucleic Acids Res.* 12: 387-395 (1984)) or MacVector 4.1 (Eastman Kodak Co., New Haven, Conn.). Thus, the present invention provides a codon usage frequency characteristic of the coding region of at least one of the
25 polynucleotides of the present invention. The number of polynucleotides that can be used to determine a codon usage frequency can be any integer from 1 to the number of polynucleotides of the present invention as provided herein. Optionally, the polynucleotides will be full-length sequences. An exemplary number of sequences for statistical analysis can be at least 1, 5, 10, 20, 50, or 100.

30

Sequence Shuffling

The present invention provides methods for sequence shuffling using polynucleotides of the present invention, and compositions resulting therefrom. Sequence

shuffling is described in PCT publication No. WO 97/20078. See also, Zhang, J.- H., *et al. Proc. Natl. Acad. Sci. USA* 94:4504-4509 (1997). Generally, sequence shuffling provides a means for generating libraries of polynucleotides having a desired characteristic which can be selected or screened for. Libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides which comprise sequence regions which have substantial sequence identity and can be homologously recombined in vitro or in vivo. The population of sequence-recombined polynucleotides comprises a subpopulation of polynucleotides which possess desired or advantageous characteristics and which can be selected by a suitable selection or screening method. The characteristics can be any property or attribute capable of being selected for or detected in a screening system, and may include properties of: an encoded protein, a transcriptional element, a sequence controlling transcription, RNA processing, RNA stability, chromatin conformation, translation, or other expression property of a gene or transgene, a replicative element, a protein-binding element, or the like, such as any feature which confers a selectable or detectable property. In some embodiments, the selected characteristic will be a decreased K_m and/or increased K_{cat} over the wild-type protein as provided herein. In other embodiments, a protein or polynucleotide generated from sequence shuffling will have a ligand binding affinity greater than the non-shuffled wild-type polynucleotide. The increase in such properties can be at least 110%, 120%, 130%, 140% or at least 150% of the wild-type value.

Generic and Consensus Sequences

Polynucleotides and polypeptides of the present invention further include those having: (a) a generic sequence of at least two homologous polynucleotides or polypeptides, respectively, of the present invention; and, (b) a consensus sequence of at least three homologous polynucleotides or polypeptides, respectively, of the present invention. The generic sequence of the present invention comprises each species of polypeptide or polynucleotide embraced by the generic polypeptide or polynucleotide, sequence, respectively. The individual species encompassed by a polynucleotide having an amino acid or nucleic acid consensus sequence can be used to generate antibodies or produce nucleic acid probes or primers to screen for homologs in other species, genera, families, orders, classes, phylums, or kingdoms. For example, a polynucleotide having a consensus sequences from a gene family of *Zea mays* can be used to generate antibody or nucleic acid

probes or primers to other *Gramineae* species such as wheat, rice, or sorghum.

Alternatively, a polynucleotide having a consensus sequence generated from orthologous genes can be used to identify or isolate orthologs of other taxa. Typically, a polynucleotide having a consensus sequence will be at least 9, 10, 15, 20, 25, 30, or 40 amino acids in length, or 20, 30, 40, 50, 100, or 150 nucleotides in length. As those of skill in the art are aware, a conservative amino acid substitution can be used for amino acids which differ amongst aligned sequence but are from the same conservative substitution group as discussed above. Optionally, no more than 1 or 2 conservative amino acids are substituted for each 10 amino acid length of consensus sequence.

Similar sequences used for generation of a consensus or generic sequence include any number and combination of allelic variants of the same gene, orthologous, or paralogous sequences as provided herein. Optionally, similar sequences used in generating a consensus or generic sequence are identified using the BLAST algorithm's smallest sum probability (P(N)). Various suppliers of sequence-analysis software are listed in chapter 7 of *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, Eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (Supplement 30). A polynucleotide sequence is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, or 0.001, and most preferably less than about 0.0001, or 0.00001. Similar polynucleotides can be aligned and a consensus or generic sequence generated using multiple sequence alignment software available from a number of commercial suppliers such as the Genetics Computer Group's (Madison, WI) PILEUP software, Vector NTI's (North Bethesda, MD) ALIGNX, or Genecode's (Ann Arbor, MI) SEQUENCHER. Conveniently, default parameters of such software can be used to generate consensus or generic sequences.

Assays for Compounds that Modulate Enzymatic Activity or Expression

The present invention also provides means for identifying compounds that bind to (e.g., substrates), and/or increase or decrease (i.e., modulate) the enzymatic activity of, catalytically active polypeptides of the present invention. The method comprises contacting a polypeptide of the present invention with a compound whose ability to bind to or modulate enzyme activity is to be determined. The polypeptide employed will have at least 20%, preferably at least 30% or 40%, more preferably at least 50% or 60%, and most

preferably at least 70% or 80% of the specific activity of the native, full-length polypeptide of the present invention (e.g., enzyme). Generally, the polypeptide will be present in a range sufficient to determine the effect of the compound, typically about 1 nM to 10 μ M. Likewise, the compound will be present in a concentration of from about 1 nM to 10 μ M.

5 Those of skill will understand that such factors as enzyme concentration, ligand concentrations (i.e., substrates, products, inhibitors, activators), pH, ionic strength, and temperature will be controlled so as to obtain useful kinetic data and determine the presence of absence of a compound that binds or modulates polypeptide activity. Methods of measuring enzyme kinetics is well known in the art. See, e.g., Segel, *Biochemical*
10 *Calculations*, 2nd ed., John Wiley and Sons, New York (1976).

Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

15

Example 1

This example describes the construction of the cDNA libraries.

Total RNA Isolation

20 The RNA for SEQ ID NO: 1 was isolated from premeiotic ear shoot tissue from maize line A632. Total RNA was isolated from corn tissues with TRIZOL Reagent (Life Technology Inc. Gaithersburg, MD) using a modification of the guanidine isothiocyanate/acid-phenol procedure described by Chomczynski and Sacchi (Chomczynski, P., and Sacchi, N. *Anal. Biochem.* 162, 156 (1987)). In brief, plant tissue
25 samples were pulverized in liquid nitrogen before the addition of the TRIZOL Reagent, and then were further homogenized with a mortar and pestle. Addition of chloroform followed by centrifugation was conducted for separation of an aqueous phase and an organic phase. The total RNA was recovered by precipitation with isopropyl alcohol from the aqueous phase.

30

Poly(A)+ RNA Isolation

The selection of poly(A)+ RNA from total RNA was performed using POLYATTRACT system (Promega Corporation, Madison, WI). In brief, biotinylated

oligo(dT) primers were used to hybridize to the 3' poly(A) tails on mRNA. The hybrids were captured using streptavidin coupled to paramagnetic particles and a magnetic separation stand. The mRNA was washed at high stringency conditions and eluted by RNase-free deionized water.

5

cDNA Library Construction

cDNA synthesis was performed and unidirectional cDNA libraries were constructed using the SUPERScript Plasmid System (Life Technology Inc. Gaithersburg, MD). The first strand of cDNA was synthesized by priming an oligo(dT) primer containing a Not I site. The reaction was catalyzed by SUPERScript Reverse Transcriptase II at 10 45°C. The second strand of cDNA was labeled with alpha-³²P-dCTP and a portion of the reaction was analyzed by agarose gel electrophoresis to determine cDNA sizes. cDNA molecules smaller than 500 base pairs and unligated adapters were removed by SEPHACRYL-S400 chromatography. The selected cDNA molecules were ligated into 15 pSPORT1 vector in between of *Not* I and *Sal* I sites.

Example 2

This example describes cDNA sequencing and library subtraction.

20 **Sequencing Template Preparation**

Individual colonies were picked and DNA was prepared either by PCR with M13 forward primers and M13 reverse primers, or by plasmid isolation. All the cDNA clones were sequenced using M13 reverse primers.

25 **Q-bot Subtraction Procedure**

cDNA libraries subjected to the subtraction procedure were plated out on 22 x 22 cm² agar plate at density of about 3,000 colonies per plate. The plates were incubated in a 37°C incubator for 12-24 hours. Colonies were picked into 384-well plates by a robot colony picker, Q-bot (GENETIX Limited). These plates were incubated overnight at 37°C.

30 Once sufficient colonies were picked, they were pinned onto 22 x 22 cm² nylon membranes using Q-bot. Each membrane contained 9,216 colonies or 36,864 colonies. These membranes were placed onto agar plate with appropriate antibiotic. The plates were incubated at 37°C for overnight.

After colonies were recovered on the second day, these filters were placed on filter paper pre-wetted with denaturing solution for four minutes, then were incubated on top of a boiling water bath for additional four minutes. The filters were then placed on filter paper pre-wetted with neutralizing solution for four minutes. After excess solution was removed by placing the filters on dry filter papers for one minute, the colony side of the filters were placed into Proteinase K solution, incubated at 37°C for 40-50 minutes. The filters were placed on dry filter papers to dry overnight. DNA was then cross-linked to nylon membrane by UV light treatment.

Colony hybridization was conducted as described by Sambrook, J., Fritsch, E.F. and Maniatis, T., (in Molecular Cloning: A laboratory Manual, 2nd Edition). The following probes were used in colony hybridization:

1. First strand cDNA from the same tissue as the library was made from to remove the most redundant clones.
2. 48-192 most redundant cDNA clones from the same library based on previous sequencing data.
3. 192 most redundant cDNA clones in the entire corn sequence database.
4. A Sal-A20 oligo nucleotide: TCG ACC CAC GCG TCC GAA AAA AAA AAA AAA AAA AAA, listed in SEQ ID NO: 3, removes clones containing a poly A tail but no cDNA.
5. cDNA clones derived from rRNA.

The image of the autoradiography was scanned into computer and the signal intensity and cold colony addresses of each colony was analyzed. Re-arraying of cold-colonies from 384 well plates to 96 well plates was conducted using Q-bot.

Example 3

This example describes identification of the gene from a computer homology search.

Gene identities were determined by conducting BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., (1990) J. Mol. Biol. 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches under default parameters for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein

Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL and DDBJ databases). The cDNA sequences were analyzed for similarity to all publicly available DNA sequences contained in the “nr” database using the BLASTN algorithm. The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the “nr” database using the BLASTX algorithm (Gish, W. and States, D. J. *Nature Genetics* 3:266-272 (1993)) provided by the NCBI. In some cases, the sequencing data from two or more clones containing overlapping segments of DNA were used to construct contiguous DNA sequences.

10 **Example 4**

This example displays structural motifs of the maize Rad50 protein sequence. The highlighted areas indicate nucleotide binding sites. The N-terminal binding site, the Walker-A motif, is known to bind ATP. The putative nuclear localization signals are identified by *italics* and the **bolding** indicates the leucine zipper motifs.

15 **Structural motifs of Maize Rad50 protein sequence (SEQ ID NO: 2)**

```

1  MSTVDKMLIK GIRSFDPDNK NVITFFKPLT LIVGPNAGAGK TTIIECLKLS
20  51  CTGELPPNSR SGHTFVHDPK VAGETETKGQ IKLRFKTAAG KDVVCIRSFQ
    101  LTQKASKMEF KAIESVLQTI NPHTGEKVCL SYRCADMRE IPALMGVSKA
    151  VLENVIFVHQ DESNWPLQDP STLKKKFDDI FSATRYTKAL EVIKKLHKDQ
25  201  MQEIKTFRK LENLQTVKDQ AHKLRENIAQ DQEKSDASKS QMEQLKEKIC
    251  GTEREILQME TSLDELRRLO GQIDIKATER STLLTQQHEK LAALSEENED
30  301  TDEELMEWQT KFEERIALLE TKISKLVRDMD DDEASYSSVL SKQNSELTHE
    351  IGKLQAEADA HLTMKHERDS DIKNICTKHN LGPVPEHPFT NDVAMNLTNR
    401  IKARLSSLEN DLLDKKKSNE DQLDVLWKHY LKINARYSEV DGQIQSKIES
35  451  MSGILRRRKD KEKERDAAEV ELSKFNLSRI DERERHMQIE VERKTLALGE
    501  RDYDSIISQK RTEVYSLEQK IKVLLREKDI INRNADERVK LGLKKDALES

```

551 SKDKLNEIVN EHKDKIKKVL RGRNPFKDM KKEINQAFWP VDKEYNELRS
601 KSQEAQELK FTQSKVTDAR EQLTKLRRDM DAKRRFLDSK LQSILQISAN
5 651 VDMFPKVLQD AMNKRDEQKR LENFANGMRE MLAPFEHLAR KNHVCPCCER
701 AFTPDEEDEF VKQORMQNSS TAERSKALAM ESSNAEALFQ QLDKLRTIYD
751 AYVKLVEETI PLAENLNQH LADESQKAQA FDDLGLVLAH VQMDRDAVEA
10 801 LLQPTDTIDR HVHEIQQLVK EVEDLEYALD SSGRGVKSLE EIQLELNFLQ
851 RTRDTLIVEV DDLRDQHRML NEDMSSAQVR WHNAREEKVK ASSILERFQK
15 901 SEEELVLLAE EKEQLIVEKK LLEESLDPLS KEKESLLQEY NALKQKLDEE
951 YHQLAERKRE FQOELDALGR LNMKIKGYLD SKKNEKLKEL QGRHVLCHSQ
1001 LQSCMAKQQR ISAELNKSKE LLQGQQLKR NIDDLNLYRK TKADVEQLTR
20 1051 DIESLEERLL SIGSLAIEA DLKRHSQEKE RLNSEFNWQ GTLSVYQSN
1101 SKHKQELKLS QYKDIEKRYT NQFLQLKTTE MANKDLDRYY TALDKALMRF
25 1151 HSMKMEEINK IIKELWQQT YRGQDIDYISI NSDSEGAGTR SYSYRVVMQT
1201 GDAELEMGR CSAGQKVLAS LIIRLALAET FCLNCGILAL DEPTTNLDGP
1251 NAESLAAALL RIMEARKGQE NFQLIVITHD ERFALHIGQR QLAEKYYRVS
30 1301 KDENQHSIIE SQEIFD*

The above examples are provided to illustrate the invention but not to limit its
35 scope. Other variants of the invention will be readily apparent to one of ordinary skill in
the art and are encompassed by the appended claims. All publications, patents, patent
applications, and computer programs cited herein are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a member selected from the group consisting of:
 - 5 (a) a polynucleotide having at least 80% sequence identity to the polynucleotide of SEQ ID NO: 1, wherein the % sequence identity is based on the entire coding region for each reference sequence and is calculated by the GAP algorithm under default parameters;
 - (b) a polynucleotide encoding the polypeptide of SEQ ID NO: 2;
 - 10 (c) a polynucleotide amplified from a *Zea mays* nucleic acid library using primers which selectively hybridize, under stringent hybridization conditions, to loci within the polynucleotide of SEQ ID NO: 1;
 - (d) a polynucleotide which selectively hybridizes, under stringent hybridization conditions and a wash in 0.1X SSC at 60°C, to the polynucleotide of SEQ ID NO: 1;
 - 15 (e) the polynucleotide of SEQ ID NO: 1;
 - (f) a polynucleotide which is complementary to a polynucleotide of (a), (b), (c), (d), or (e); and
 - (g) a polynucleotide comprising at least 30 contiguous nucleotides from a polynucleotide of (a), (b), (c), (d), (e), or (f).
 - 20
2. A recombinant expression cassette, comprising a member of claim 1 operably linked, in sense or anti-sense orientation, to a promoter.
- 25 3. A host cell comprising the recombinant expression cassette of claim 2.
4. A transgenic plant comprising a recombinant expression cassette of claim 2.
5. The transgenic plant of claim 4, wherein said plant is a monocot.
- 30 6. The transgenic plant of claim 4, wherein said plant is a dicot.

7. The transgenic plant of claim 4, wherein said plant is selected from the group consisting of: maize, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice, barley, and millet.

5 8. A transgenic seed from the transgenic plant of claim 4.

9. A method of modulating the level of Rad50 in a plant, comprising:

- (a) introducing into a plant cell a recombinant expression cassette comprising a
Rad50 polynucleotide of claim 1 operably linked to a promoter;
10 (b) culturing the plant cell under plant cell growing conditions;
(c) regenerating a whole plant which possesses the transformed genotype; and
(d) inducing expression of said polynucleotide for a time sufficient to modulate the
level of Rad50 in said plant.

15 10. The method of claim 9, wherein the plant is maize.

11. An isolated protein comprising a member selected from the group consisting
of:

- (a) a polypeptide of at least 20 contiguous amino acids from the polypeptide of
20 SEQ ID NO: 2;
(b) the polypeptide of SEQ ID NO: 2;
(c) a polypeptide having at least 80% sequence identity to, and having at least one
linear epitope in common with, the polypeptide of SEQ ID NO: 2, wherein said
sequence identity is determined using the GAP program under default
25 parameters; and
(d) at least one polypeptide encoded by a member of claim 1.

SEQUENCE LISTING

<110> Pioneer Hi-Bred International, Inc.

<120> Maize Rad50 Orthologue and Uses Thereof

<130> 1116-PCT

<150> 60/132,575

<151> 1999-05-05

<160> 3

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 4492

<212> DNA

<213> Zea mays

<220>

<221> CDS

<222> (292) ... (4239)

<400> 1

```

aattcggcac gagtggatcc attagcacc atagccgtac aaaaccctaa gaaccctaac      60
cggtaaaaaa ccataaaaac cctaacgccg ctgaagactc caaaaaaacg cgattttctc      120
ctccactgcc cctccttttc tctttccaat cgttttgcaa tcactacgag cgtaatgaat      180
agaagttgat agggagatag catccgcaat ctaggtttgg ggcaatcgct ctggccagac      240
tggatcggag tgcaagtcgt agagggaggc acttgggggc cgtggggcaa g atg agc      297
                                     Met Ser
                                     1

acc gtt gac aag atg ctg atc aag ggg att cgg agc ttc gat ccg gac      345
Thr Val Asp Lys Met Leu Ile Lys Gly Ile Arg Ser Phe Asp Pro Asp
      5                               10                               15

aat aag aac gtc atc acc ttc ttc aag ccg ctc acc ctc atc gtt ggc      393
Asn Lys Asn Val Ile Thr Phe Phe Lys Pro Leu Thr Leu Ile Val Gly
      20                               25                               30

ccc aac ggt gct ggc aag acc acg atc atc gag tgc ctg aag ctt tct      441
Pro Asn Gly Ala Gly Lys Thr Thr Ile Ile Glu Cys Leu Lys Leu Ser
      35                               40                               45                               50

tgc acc ggc gag ctg ccc ccc aac tcc cgc tct ggc cac acc ttc gtc      489
Cys Thr Gly Glu Leu Pro Pro Asn Ser Arg Ser Gly His Thr Phe Val
      55                               60                               65

cac gac ccc aag gta gct ggc gag acg gaa aca aaa gga caa att aag      537
His Asp Pro Lys Val Ala Gly Glu Thr Glu Thr Lys Gly Gln Ile Lys
      70                               75                               80

ttg cgg ttt aag act gca gca gga aag gat gtg gcg tgc atc cgg tcc      585
Leu Arg Phe Lys Thr Ala Ala Gly Lys Asp Val Val Cys Ile Arg Ser
      85                               90                               95

ttc cag ctt acc caa aag gca tca aag atg gag ttt aag gca att gaa      633
Phe Gln Leu Thr Gln Lys Ala Ser Lys Met Glu Phe Lys Ala Ile Glu
      100                               105                               110

```

agc gtc ctc cag act ata aat cca cac aca ggg gag aaa gtc tgc ctc	681
Ser Val Leu Gln Thr Ile Asn Pro His Thr Gly Glu Lys Val Cys Leu	
115 120 125 130	
agc tac aga tgt gct gac atg gat aga gag att cct gcc tta atg ggt	729
Ser Tyr Arg Cys Ala Asp Met Asp Arg Glu Ile Pro Ala Leu Met Gly	
135 140 145	
gtt tcg aag gcc gta ctg gag aat gtt ata ttt gtt cac caa gat gaa	777
Val Ser Lys Ala Val Leu Glu Asn Val Ile Phe Val His Gln Asp Glu	
150 155 160	
tcc aat tgg cca ttg cag gac ccg tca aca ctt aag aag aag ttc gat	825
Ser Asn Trp Pro Leu Gln Asp Pro Ser Thr Leu Lys Lys Lys Phe Asp	
165 170 175	
gac atc ttc tct gcc aca cgc tat acg aaa gct ctt gaa gtc ata aag	873
Asp Ile Phe Ser Ala Thr Arg Tyr Thr Lys Ala Leu Glu Val Ile Lys	
180 185 190	
aaa ctt cac aag gat caa atg caa gag atc aag act ttt agg tta aag	921
Lys Leu His Lys Asp Gln Met Gln Glu Ile Lys Thr Phe Arg Leu Lys	
195 200 205 210	
ctg gag aac ctt cag act gta aaa gac caa gca cat aag ctg cgt gaa	969
Leu Glu Asn Leu Gln Thr Val Lys Asp Gln Ala His Lys Leu Arg Glu	
215 220 225	
aat att gct caa gat caa gaa aag tca gat gcc tca aaa tct cag atg	1017
Asn Ile Ala Gln Asp Gln Glu Lys Ser Asp Ala Ser Lys Ser Gln Met	
230 235 240	
gag caa ctg aag gaa aag atc tgt ggt acc gag aga gaa atc ctg caa	1065
Glu Gln Leu Lys Glu Lys Ile Cys Gly Thr Glu Arg Glu Ile Leu Gln	
245 250 255	
atg gaa aca agt ttg gat gaa ctg aga aga ctt cag gga caa att gac	1113
Met Glu Thr Ser Leu Asp Glu Leu Arg Arg Leu Gln Gly Gln Ile Asp	
260 265 270	
atc aag gca aca gag aga agt aca tta ctt acg cag cag cat gaa aag	1161
Ile Lys Ala Thr Glu Arg Ser Thr Leu Leu Thr Gln Gln His Glu Lys	
275 280 285 290	
ctt gct gca ctt tct gag gaa aat gaa gat acc gat gag gaa cta atg	1209
Leu Ala Ala Leu Ser Glu Glu Asn Glu Asp Thr Asp Glu Glu Leu Met	
295 300 305	
gaa tgg caa aca aaa ttt gaa gaa agg att gcg tta cta gaa aca aaa	1257
Glu Trp Gln Thr Lys Phe Glu Glu Arg Ile Ala Leu Leu Glu Thr Lys	
310 315 320	
atc agt aaa ctt gta aga gat atg gat gat gaa gca tct tat agc tcc	1305
Ile Ser Lys Leu Val Arg Asp Met Asp Asp Glu Ala Ser Tyr Ser Ser	
325 330 335	
gtt ctg tcc aaa caa aat tct gaa tta aca cat gaa att gga aag ctc	1353
Val Leu Ser Lys Gln Asn Ser Glu Leu Thr His Glu Ile Gly Lys Leu	
340 345 350	
cag gca gaa gct gat gct cac ctg act atg aag cat gaa cga gac tca	1401
Gln Ala Glu Ala Asp Ala His Leu Thr Met Lys His Glu Arg Asp Ser	

355	360	365	370	
gac ata aaa aat ata tgc act aaa cat aat ctt ggg ccg gtt cct gaa				1449
Asp Ile Lys Asn Ile Cys Thr Lys His Asn Leu Gly Pro Val Pro Glu				
	375	380	385	
cat ccc ttt acg aat gat gtt gct atg aac ctt aca aac agg att aaa				1497
His Pro Phe Thr Asn Asp Val Ala Met Asn Leu Thr Asn Arg Ile Lys				
	390	395	400	
gcg aga cta tca agt ctt gag aat gat ttg ctg gat aag aag aaa tcc				1545
Ala Arg Leu Ser Ser Leu Glu Asn Asp Leu Leu Asp Lys Lys Lys Ser				
	405	410	415	
aat gaa gat cag tta gat gtt ttg tgg aaa cac tat ctt aaa ata aat				1593
Asn Glu Asp Gln Leu Asp Val Leu Trp Lys His Tyr Leu Lys Ile Asn				
	420	425	430	
gct cgc tac tcc gaa gtt gat ggt cag ata caa tct aag att gaa tcc				1641
Ala Arg Tyr Ser Glu Val Asp Gly Gln Ile Gln Ser Lys Ile Glu Ser				
	435	440	445	450
atg tca ggc att tta aga cgg aga aaa gat aaa gag aaa gaa cgc gat				1689
Met Ser Gly Ile Leu Arg Arg Arg Lys Asp Lys Glu Lys Glu Arg Asp				
	455	460	465	
gct gca gaa gtg gag ctt tca aaa ttt aat cta tcc cgt atc gat gag				1737
Ala Ala Glu Val Glu Leu Ser Lys Phe Asn Leu Ser Arg Ile Asp Glu				
	470	475	480	
agg gag aga cat atg caa att gaa gtc gag agg aag aca ctt gcg ctt				1785
Arg Glu Arg His Met Gln Ile Glu Val Glu Arg Lys Thr Leu Ala Leu				
	485	490	495	
gga gaa aga gac tat gat tca att ata agt cag aaa cga aca gaa gta				1833
Gly Glu Arg Asp Tyr Asp Ser Ile Ile Ser Gln Lys Arg Thr Glu Val				
	500	505	510	
tat agt ttg gaa cag aaa ata aaa gtg ctt ctg cgg gag aaa gat ata				1881
Tyr Ser Leu Glu Gln Lys Ile Lys Val Leu Leu Arg Glu Lys Asp Ile				
	515	520	525	530
ata aat aga aat gct gat gaa aga gta aaa ctg ggt ttg aag aag gat				1929
Ile Asn Arg Asn Ala Asp Glu Arg Val Lys Leu Gly Leu Lys Lys Asp				
	535	540	545	
gca ttg gaa agc agc aag gac aag ctc aat gag ata gtt aat gag cat				1977
Ala Leu Glu Ser Ser Lys Asp Lys Leu Asn Glu Ile Val Asn Glu His				
	550	555	560	
aag gat aaa atc aaa aag gta ctt agg ggg agg aat cct ttt gag aag				2025
Lys Asp Lys Ile Lys Lys Val Leu Arg Gly Arg Asn Pro Phe Glu Lys				
	565	570	575	
gat atg aag aag gag atc aat caa gcc ttt tgg cct gtg gac aag gaa				2073
Asp Met Lys Lys Glu Ile Asn Gln Ala Phe Trp Pro Val Asp Lys Glu				
	580	585	590	
tac aat gag tta aga tca aaa tcc cag gaa gca gag caa gag ctt aaa				2121
Tyr Asn Glu Leu Arg Ser Lys Ser Gln Glu Ala Glu Gln Glu Leu Lys				
	595	600	605	610

ttt act cag agc aaa gta act gat gct aga gaa caa ttg aca aaa ctt	2169
Phe Thr Gln Ser Lys Val Thr Asp Ala Arg Glu Gln Leu Thr Lys Leu	
615 620 625	
cga aga gat atg gat gca aaa aga aga ttc ctg gac tcg aaa ctt caa	2217
Arg Arg Asp Met Asp Ala Lys Arg Arg Phe Leu Asp Ser Lys Leu Gln	
630 635 640	
tct att tta cag ata tct gct aat gtt gac atg ttt ccc aaa gtt cta	2265
Ser Ile Leu Gln Ile Ser Ala Asn Val Asp Met Phe Pro Lys Val Leu	
645 650 655	
caa gac gcc atg aac aaa aga gat gaa cag aaa aga tta gag aat ttc	2313
Gln Asp Ala Met Asn Lys Arg Asp Glu Gln Lys Arg Leu Glu Asn Phe	
660 665 670	
gca aat gga atg cgg gaa atg ctt gca cct ttt gaa cat ttg gct cgg	2361
Ala Asn Gly Met Arg Glu Met Leu Ala Pro Phe Glu His Leu Ala Arg	
675 680 685 690	
aag aat cat gta tgc cca tgc tgt gaa cgt gct ttc aca cct gat gag	2409
Lys Asn His Val Cys Pro Cys Cys Glu Arg Ala Phe Thr Pro Asp Glu	
695 700 705	
gag gat gag ttc gtg aag aaa caa agg atg caa aac tca agt act gca	2457
Glu Asp Glu Phe Val Lys Lys Gln Arg Met Gln Asn Ser Ser Thr Ala	
710 715 720	
gag aga tct aaa gct ctg gca atg gaa tca tca aat gct gaa gct ctt	2505
Glu Arg Ser Lys Ala Leu Ala Met Glu Ser Ser Asn Ala Glu Ala Leu	
725 730 735	
ttt cag caa ttg gat aaa ctt cgg act atc tat gat gct tat gtg aag	2553
Phe Gln Gln Leu Asp Lys Leu Arg Thr Ile Tyr Asp Ala Tyr Val Lys	
740 745 750	
ctg gta gaa gaa acc ata cct cta gca gag aaa aac ttg aat caa cat	2601
Leu Val Glu Glu Thr Ile Pro Leu Ala Glu Lys Asn Leu Asn Gln His	
755 760 765 770	
ttg gcg gat gaa agt cag aag gcg cag gca ttt gat gat ctt ttg ggt	2649
Leu Ala Asp Glu Ser Gln Lys Ala Gln Ala Phe Asp Asp Leu Leu Gly	
775 780 785	
gtt ctt gcc cat gtt caa atg gac agg gat gca gtg gaa gcc tta tta	2697
Val Leu Ala His Val Gln Met Asp Arg Asp Ala Val Glu Ala Leu Leu	
790 795 800	
caa ccc act gat act att gac agg cat gta cat gaa att caa cag cta	2745
Gln Pro Thr Asp Thr Ile Asp Arg His Val His Glu Ile Gln Gln Leu	
805 810 815	
gtc aaa gaa gta gaa gat ctt gaa tat gca ctt gat tct agt ggc cga	2793
Val Lys Glu Val Glu Asp Leu Glu Tyr Ala Leu Asp Ser Ser Gly Arg	
820 825 830	
ggg gtc aag tct ttg gag gaa att caa ctg gag ctg aac ttt ctg cag	2841
Gly Val Lys Ser Leu Glu Glu Ile Gln Leu Leu Asn Phe Leu Gln	
835 840 845 850	
aga aca agg gac aca ttg att gtc gaa gtg gat gat ctt aga gat caa	2889
Arg Thr Arg Asp Thr Leu Ile Val Glu Val Asp Asp Leu Arg Asp Gln	

				855				860				865							
cat	aga	atg	cta	aat	gaa	gat	atg	tca	agt	gct	cag	gtg	aga	tgg	cac	2937			
His	Arg	Met	Leu	Asn	Glu	Asp	Met	Ser	Ser	Ala	Gln	Val	Arg	Trp	His				
870								875				880							
aat	gct	cgg	gaa	gag	aaa	gtg	aaa	gct	tct	agc	ata	ttg	gaa	aga	ttc	2985			
Asn	Ala	Arg	Glu	Glu	Lys	Val	Lys	Ala	Ser	Ser	Ile	Leu	Glu	Arg	Phe				
885								890				895							
caa	aaa	tct	gaa	gag	gaa	ttg	gtg	ctt	cta	gct	gag	gaa	aaa	gaa	caa	3033			
Gln	Lys	Ser	Glu	Glu	Glu	Leu	Val	Leu	Leu	Ala	Glu	Glu	Lys	Glu	Gln				
900								905				910							
ctg	att	gta	gaa	aag	aag	ctt	tta	gaa	gag	tct	ctt	gat	cca	ttg	tcc	3081			
Leu	Ile	Val	Glu	Lys	Lys	Leu	Leu	Glu	Glu	Ser	Leu	Asp	Pro	Leu	Ser				
915				920								925				930			
aaa	gag	aaa	gag	agc	ttg	ttg	caa	gag	tat	aat	gct	ttg	aag	caa	aag	3129			
Lys	Glu	Lys	Glu	Ser	Leu	Leu	Gln	Glu	Tyr	Asn	Ala	Leu	Lys	Gln	Lys				
				935				940				945							
ctg	gat	gaa	gag	tat	cat	cag	ctt	gca	gaa	aga	aaa	agg	gag	ttc	cag	3177			
Leu	Asp	Glu	Glu	Tyr	His	Gln	Leu	Ala	Glu	Arg	Lys	Arg	Glu	Phe	Gln				
				950				955				960							
caa	gaa	ctt	gat	gct	ctt	gga	aga	ctt	aat	atg	aag	ata	aaa	ggg	tac	3225			
Gln	Glu	Leu	Asp	Ala	Leu	Gly	Arg	Leu	Asn	Met	Lys	Ile	Lys	Gly	Tyr				
965								970				975							
ttg	gat	tcc	aag	aaa	aac	gaa	aag	ctt	aag	gaa	ttg	cag	gga	agg	cat	3273			
Leu	Asp	Ser	Lys	Lys	Asn	Glu	Lys	Leu	Lys	Glu	Leu	Gln	Gly	Arg	His				
980				985								990							
gtt	ctt	tgc	cat	tct	cag	tta	cag	agt	tgc	atg	gca	aaa	cag	caa	aga	3321			
Val	Leu	Cys	His	Ser	Gln	Leu	Gln	Ser	Cys	Met	Ala	Lys	Gln	Gln	Arg				
995				1000								1005				1010			
ata	tca	gct	gag	tta	aac	aag	agc	aaa	gaa	cta	ctg	cag	ggc	cag	ggc	3369			
Ile	Ser	Ala	Glu	Leu	Asn	Lys	Ser	Lys	Glu	Leu	Leu	Gln	Gly	Gln	Gly				
				1015				1020				1025							
cag	ttg	aaa	aga	aac	att	gat	gac	aat	ctc	aag	tac	agg	aaa	aca	aag	3417			
Gln	Leu	Lys	Arg	Asn	Ile	Asp	Asp	Asn	Leu	Lys	Tyr	Arg	Lys	Thr	Lys				
				1030				1035				1040							
gct	gat	gtg	gaa	caa	ctt	act	cgt	gat	ata	gaa	tca	ctt	gaa	gaa	agg	3465			
Ala	Asp	Val	Glu	Gln	Leu	Thr	Arg	Asp	Ile	Glu	Ser	Leu	Glu	Glu	Arg				
1045								1050				1055							
ctg	ctt	tca	ata	ggt	agc	ttg	tct	gct	ata	gaa	gct	gat	ctg	aaa	cgc	3513			
Leu	Leu	Ser	Ile	Gly	Ser	Leu	Ser	Ala	Ile	Glu	Ala	Asp	Leu	Lys	Arg				
1060				1065								1070							
cat	tct	caa	gaa	aaa	gag	agg	ctt	aat	tca	gaa	ttt	aac	agg	tgg	caa	3561			
His	Ser	Gln	Glu	Lys	Glu	Arg	Leu	Asn	Ser	Glu	Phe	Asn	Arg	Trp	Gln				
1075				1080								1085				1090			
gga	aca	ctt	tct	gtt	tat	caa	agt	aat	att	tca	aag	cac	aaa	caa	gag	3609			
Gly	Thr	Leu	Ser	Val	Tyr	Gln	Ser	Asn	Ile	Ser	Lys	His	Lys	Gln	Glu				
				1095				1100				1105							

ctt aaa ctg tca cag tac aag gat atc gag aag cga tat act aat caa 3657
 Leu Lys Leu Ser Gln Tyr Lys Asp Ile Glu Lys Arg Tyr Thr Asn Gln
 1110 1115 1120

ttt ctc cag ctt aag aca act gaa atg gca aac aag gac ttg gac aga 3705
 Phe Leu Gln Leu Lys Thr Thr Glu Met Ala Asn Lys Asp Leu Asp Arg
 1125 1130 1135

tat tat act gct tta gac aag gct ctt atg cgg ttc cac agc atg aag 3753
 Tyr Tyr Thr Ala Leu Asp Lys Ala Leu Met Arg Phe His Ser Met Lys
 1140 1145 1150

atg gag gag ata aat aaa ata atc aag gaa ctg tgg caa cag aca tac 3801
 Met Glu Glu Ile Asn Lys Ile Ile Lys Glu Leu Trp Gln Gln Thr Tyr
 1155 1160 1165 1170

aga ggc cag gat att gat tac ata agc ata aat tct gat tct gag ggt 3849
 Arg Gly Gln Asp Ile Asp Tyr Ile Ser Ile Asn Ser Asp Ser Glu Gly
 1175 1180 1185

gct ggc act cga tca tac agc tac cgc gtt gtt atg caa act ggt gat 3897
 Ala Gly Thr Arg Ser Tyr Ser Tyr Arg Val Val Met Gln Thr Gly Asp
 1190 1195 1200

gct gag ctg gaa atg cga ggg cgc tgc agt gct ggt cag aag gtt ctt 3945
 Ala Glu Leu Glu Met Arg Gly Arg Cys Ser Ala Gly Gln Lys Val Leu
 1205 1210 1215

gct tct ctt ata atc aga cta gca ctt gcg gaa act ttc tgc ctg aac 3993
 Ala Ser Leu Ile Ile Arg Leu Ala Leu Ala Glu Thr Phe Cys Leu Asn
 1220 1225 1230

tgc ggt ata ttg gct ttg gat gag cca act acg aat cta gat ggg cca 4041
 Cys Gly Ile Leu Ala Leu Asp Glu Pro Thr Thr Asn Leu Asp Gly Pro
 1235 1240 1245 1250

aat gca gag agt ctt gct gct gcg ctg ttg aga ata atg gaa gcc agg 4089
 Asn Ala Glu Ser Leu Ala Ala Ala Leu Leu Arg Ile Met Glu Ala Arg
 1255 1260 1265

aaa ggg cag gag aac ttc cag ttg att gta atc act cat gat gag aga 4137
 Lys Gly Gln Glu Asn Phe Gln Leu Ile Val Ile Thr His Asp Glu Arg
 1270 1275 1280

ttt gcc cat ctt atc ggt caa agg cag ctt gct gag aag tac tat cga 4185
 Phe Ala His Leu Ile Gly Gln Arg Gln Leu Ala Glu Lys Tyr Tyr Arg
 1285 1290 1295

gtc tcc aag gat gag aac cag cac agc ata att gaa tcc caa gag ata 4233
 Val Ser Lys Asp Glu Asn Gln His Ser Ile Ile Glu Ser Gln Glu Ile
 1300 1305 1310

ttt gac taagggtggt ctaggaggct gtagcacgca ctcgtttgct agtcgaatcc 4289
 Phe Asp
 1315

agttaattta tgccaagtac tgggtgccaga gcaatgttaa caagcttttag gaggctctgt 4349
 tacgccgtta cgtcagttgc gtgaaacctt tccttcggtg ttgtatactt atttaactctg 4409
 gccagaggat ggaatgtgtg cactgggtga tggatgtttc acgacatcaa tgaatgtttc 4469
 acaatctagc atcaaaaaaa aaa 4492

<211> 1316
 <212> PRT
 <213> Zea mays

<400> 2

Met	Ser	Thr	Val	Asp	Lys	Met	Leu	Ile	Lys	Gly	Ile	Arg	Ser	Phe	Asp
1				5					10					15	
Pro	Asp	Asn	Lys	Asn	Val	Ile	Thr	Phe	Phe	Lys	Pro	Leu	Thr	Leu	Ile
			20					25					30		
Val	Gly	Pro	Asn	Gly	Ala	Gly	Lys	Thr	Thr	Ile	Ile	Glu	Cys	Leu	Lys
		35				40						45			
Leu	Ser	Cys	Thr	Gly	Glu	Leu	Pro	Pro	Asn	Ser	Arg	Ser	Gly	His	Thr
	50					55					60				
Phe	Val	His	Asp	Pro	Lys	Val	Ala	Gly	Glu	Thr	Glu	Thr	Lys	Gly	Gln
65					70					75					80
Ile	Lys	Leu	Arg	Phe	Lys	Thr	Ala	Ala	Gly	Lys	Asp	Val	Val	Cys	Ile
				85					90					95	
Arg	Ser	Phe	Gln	Leu	Thr	Gln	Lys	Ala	Ser	Lys	Met	Glu	Phe	Lys	Ala
			100					105					110		
Ile	Glu	Ser	Val	Leu	Gln	Thr	Ile	Asn	Pro	His	Thr	Gly	Glu	Lys	Val
		115					120					125			
Cys	Leu	Ser	Tyr	Arg	Cys	Ala	Asp	Met	Asp	Arg	Glu	Ile	Pro	Ala	Leu
	130					135					140				
Met	Gly	Val	Ser	Lys	Ala	Val	Leu	Glu	Asn	Val	Ile	Phe	Val	His	Gln
145					150					155					160
Asp	Glu	Ser	Asn	Trp	Pro	Leu	Gln	Asp	Pro	Ser	Thr	Leu	Lys	Lys	Lys
			165						170					175	
Phe	Asp	Asp	Ile	Phe	Ser	Ala	Thr	Arg	Tyr	Thr	Lys	Ala	Leu	Glu	Val
			180					185					190		
Ile	Lys	Lys	Leu	His	Lys	Asp	Gln	Met	Gln	Glu	Ile	Lys	Thr	Phe	Arg
		195					200					205			
Leu	Lys	Leu	Glu	Asn	Leu	Gln	Thr	Val	Lys	Asp	Gln	Ala	His	Lys	Leu
	210					215					220				
Arg	Glu	Asn	Ile	Ala	Gln	Asp	Gln	Glu	Lys	Ser	Asp	Ala	Ser	Lys	Ser
225					230					235					240
Gln	Met	Glu	Gln	Leu	Lys	Glu	Lys	Ile	Cys	Gly	Thr	Glu	Arg	Glu	Ile
			245						250					255	
Leu	Gln	Met	Glu	Thr	Ser	Leu	Asp	Glu	Leu	Arg	Arg	Leu	Gln	Gly	Gln
		260						265					270		
Ile	Asp	Ile	Lys	Ala	Thr	Glu	Arg	Ser	Thr	Leu	Leu	Thr	Gln	Gln	His
		275					280					285			
Glu	Lys	Leu	Ala	Ala	Leu	Ser	Glu	Glu	Asn	Glu	Asp	Thr	Asp	Glu	Glu
	290					295					300				
Leu	Met	Glu	Trp	Gln	Thr	Lys	Phe	Glu	Glu	Arg	Ile	Ala	Leu	Leu	Glu
305					310					315					320
Thr	Lys	Ile	Ser	Lys	Leu	Val	Arg	Asp	Met	Asp	Asp	Glu	Ala	Ser	Tyr
			325						330					335	
Ser	Ser	Val	Leu	Ser	Lys	Gln	Asn	Ser	Glu	Leu	Thr	His	Glu	Ile	Gly
			340					345					350		
Lys	Leu	Gln	Ala	Glu	Ala	Asp	Ala	His	Leu	Thr	Met	Lys	His	Glu	Arg
		355					360					365			
Asp	Ser	Asp	Ile	Lys	Asn	Ile	Cys	Thr	Lys	His	Asn	Leu	Gly	Pro	Val
	370					375					380				
Pro	Glu	His	Pro	Phe	Thr	Asn	Asp	Val	Ala	Met	Asn	Leu	Thr	Asn	Arg
385					390					395					400
Ile	Lys	Ala	Arg	Leu	Ser	Ser	Leu	Glu	Asn	Asp	Leu	Leu	Asp	Lys	Lys
			405						410					415	
Lys	Ser	Asn	Glu	Asp	Gln	Leu	Asp	Val	Leu	Trp	Lys	His	Tyr	Leu	Lys
		420						425					430		
Ile	Asn	Ala	Arg	Tyr	Ser	Glu	Val	Asp	Gly	Gln	Ile	Gln	Ser	Lys	Ile
	435						440					445			
Glu	Ser	Met	Ser	Gly	Ile	Leu	Arg	Arg	Arg	Lys	Asp	Lys	Glu	Lys	Glu

450	455	460
Arg Asp Ala Ala Glu Val Glu Leu Ser Lys Phe Asn Leu Ser Arg Ile		
465	470	475
Asp Glu Arg Glu Arg His Met Gln Ile Glu Val Glu Arg Lys Thr Leu		480
	485	490
Ala Leu Gly Glu Arg Asp Tyr Asp Ser Ile Ile Ser Gln Lys Arg Thr		495
	500	505
Glu Val Tyr Ser Leu Glu Gln Lys Ile Lys Val Leu Leu Arg Glu Lys		510
	515	520
Asp Ile Ile Asn Arg Asn Ala Asp Glu Arg Val Lys Leu Gly Leu Lys		525
	530	535
Lys Asp Ala Leu Glu Ser Ser Lys Asp Lys Leu Asn Glu Ile Val Asn		540
545	550	555
Glu His Lys Asp Lys Ile Lys Lys Val Leu Arg Gly Arg Asn Pro Phe		560
	565	570
Glu Lys Asp Met Lys Lys Glu Ile Asn Gln Ala Phe Trp Pro Val Asp		575
	580	585
Lys Glu Tyr Asn Glu Leu Arg Ser Lys Ser Gln Glu Ala Glu Gln Glu		590
	595	600
Leu Lys Phe Thr Gln Ser Lys Val Thr Asp Ala Arg Glu Gln Leu Thr		605
	610	615
Lys Leu Arg Arg Asp Met Asp Ala Lys Arg Arg Phe Leu Asp Ser Lys		620
625	630	635
Leu Gln Ser Ile Leu Gln Ile Ser Ala Asn Val Asp Met Phe Pro Lys		640
	645	650
Val Leu Gln Asp Ala Met Asn Lys Arg Asp Glu Gln Lys Arg Leu Glu		655
	660	665
Asn Phe Ala Asn Gly Met Arg Glu Met Leu Ala Pro Phe Glu His Leu		670
	675	680
Ala Arg Lys Asn His Val Cys Pro Cys Cys Glu Arg Ala Phe Thr Pro		685
	690	695
Asp Glu Glu Asp Glu Phe Val Lys Lys Gln Arg Met Gln Asn Ser Ser		700
705	710	715
Thr Ala Glu Arg Ser Lys Ala Leu Ala Met Glu Ser Ser Asn Ala Glu		720
	725	730
Ala Leu Phe Gln Gln Leu Asp Lys Leu Arg Thr Ile Tyr Asp Ala Tyr		735
	740	745
Val Lys Leu Val Glu Glu Thr Ile Pro Leu Ala Glu Lys Asn Leu Asn		750
	755	760
Gln His Leu Ala Asp Glu Ser Gln Lys Ala Gln Ala Phe Asp Asp Leu		765
	770	775
Leu Gly Val Leu Ala His Val Gln Met Asp Arg Asp Ala Val Glu Ala		780
785	790	795
Leu Leu Gln Pro Thr Asp Thr Ile Asp Arg His Val His Glu Ile Gln		800
	805	810
Gln Leu Val Lys Glu Val Glu Asp Leu Glu Tyr Ala Leu Asp Ser Ser		815
	820	825
Gly Arg Gly Val Lys Ser Leu Glu Glu Ile Gln Leu Glu Leu Asn Phe		830
	835	840
Leu Gln Arg Thr Arg Asp Thr Leu Ile Val Glu Val Asp Asp Leu Arg		845
	850	855
Asp Gln His Arg Met Leu Asn Glu Asp Met Ser Ser Ala Gln Val Arg		860
865	870	875
Trp His Asn Ala Arg Glu Glu Lys Val Lys Ala Ser Ser Ile Leu Glu		880
	885	890
Arg Phe Gln Lys Ser Glu Glu Glu Leu Val Leu Leu Ala Glu Glu Lys		895
	900	905
Glu Gln Leu Ile Val Glu Lys Lys Leu Leu Glu Glu Ser Leu Asp Pro		910
	915	920
Leu Ser Lys Glu Lys Glu Ser Leu Leu Gln Glu Tyr Asn Ala Leu Lys		925
	930	935
Gln Lys Leu Asp Glu Glu Tyr His Gln Leu Ala Glu Arg Lys Arg Glu		940

945					950					955					960				
Phe	Gln	Gln	Glu	Leu	Asp	Ala	Leu	Gly	Arg	Leu	Asn	Met	Lys	Ile	Lys				
				965					970					975					
Gly	Tyr	Leu	Asp	Ser	Lys	Lys	Asn	Glu	Lys	Leu	Lys	Glu	Leu	Gln	Gly				
				980					985					990					
Arg	His	Val	Leu	Cys	His	Ser	Gln	Leu	Gln	Ser	Cys	Met	Ala	Lys	Gln				
				995					1000					1005					
Gln	Arg	Ile	Ser	Ala	Glu	Leu	Asn	Lys	Ser	Lys	Glu	Leu	Leu	Gln	Gly				
				1010					1015					1020					
Gln	Gly	Gln	Leu	Lys	Arg	Asn	Ile	Asp	Asp	Asn	Leu	Lys	Tyr	Arg	Lys				
				1025					1030					1035	1040				
Thr	Lys	Ala	Asp	Val	Glu	Gln	Leu	Thr	Arg	Asp	Ile	Glu	Ser	Leu	Glu				
				1045					1050					1055					
Glu	Arg	Leu	Leu	Ser	Ile	Gly	Ser	Leu	Ser	Ala	Ile	Glu	Ala	Asp	Leu				
				1060					1065					1070					
Lys	Arg	His	Ser	Gln	Glu	Lys	Glu	Arg	Leu	Asn	Ser	Glu	Phe	Asn	Arg				
				1075					1080					1085					
Trp	Gln	Gly	Thr	Leu	Ser	Val	Tyr	Gln	Ser	Asn	Ile	Ser	Lys	His	Lys				
				1090					1095					1100					
Gln	Glu	Leu	Lys	Leu	Ser	Gln	Tyr	Lys	Asp	Ile	Glu	Lys	Arg	Tyr	Thr				
				1105					1110					1115	1120				
Asn	Gln	Phe	Leu	Gln	Leu	Lys	Thr	Thr	Glu	Met	Ala	Asn	Lys	Asp	Leu				
				1125					1130					1135					
Asp	Arg	Tyr	Tyr	Thr	Ala	Leu	Asp	Lys	Ala	Leu	Met	Arg	Phe	His	Ser				
				1140					1145					1150					
Met	Lys	Met	Glu	Glu	Ile	Asn	Lys	Ile	Ile	Lys	Glu	Leu	Trp	Gln	Gln				
				1155					1160					1165					
Thr	Tyr	Arg	Gly	Gln	Asp	Ile	Asp	Tyr	Ile	Ser	Ile	Asn	Ser	Asp	Ser				
				1170					1175					1180					
Glu	Gly	Ala	Gly	Thr	Arg	Ser	Tyr	Ser	Tyr	Arg	Val	Val	Met	Gln	Thr				
				1185					1190					1195	1200				
Gly	Asp	Ala	Glu	Leu	Glu	Met	Arg	Gly	Arg	Cys	Ser	Ala	Gly	Gln	Lys				
				1205					1210					1215					
Val	Leu	Ala	Ser	Leu	Ile	Ile	Arg	Leu	Ala	Leu	Ala	Glu	Thr	Phe	Cys				
				1220					1225					1230					
Leu	Asn	Cys	Gly	Ile	Leu	Ala	Leu	Asp	Glu	Pro	Thr	Thr	Asn	Leu	Asp				
				1235					1240					1245					
Gly	Pro	Asn	Ala	Glu	Ser	Leu	Ala	Ala	Ala	Leu	Leu	Arg	Ile	Met	Glu				
				1250					1255					1260					
Ala	Arg	Lys	Gly	Gln	Glu	Asn	Phe	Gln	Leu	Ile	Val	Ile	Thr	His	Asp				
				1265					1270					1275	1280				
Glu	Arg	Phe	Ala	His	Leu	Ile	Gly	Gln	Arg	Gln	Leu	Ala	Glu	Lys	Tyr				
				1285					1290					1295					
Tyr	Arg	Val	Ser	Lys	Asp	Glu	Asn	Gln	His	Ser	Ile	Ile	Glu	Ser	Gln				
				1300					1305					1310					
Glu	Ile	Phe	Asp																
				1315															

```
<210> 3
<211> 36
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> Designed oligonucleotide based upon an adaptor
      used for cDNA library construction and poly(dT) to
      remove clones which have a poly(A) tail but no
      cDNA insert.
```

```
<400> 3
tcgaccacq cgtccqaaaa aaaaaaaaaa aaaaaa
```

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/11086

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/82 C07K14/415 C12N5/14 C12N15/63		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, STRAND		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 38306 A (GENELABS TECH INC) 3 September 1998 (1998-09-03) SEQ ID NO:54; SEQ ID NO:148 ---	1-11
P,A	GALLEGRO M.E. ET AL.: "The Rad50 homolog of Arabidopsis; Arabidopsis thaliana DNA repair-recombination protein (RAD50) mRNA, complete cds." EMBL DATABASE ENTRY AF168748; ACCESSION NO. AF168748, 3 March 2000 (2000-03-03), XP002150323 --- -/--	1-11
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">17 October 2000</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">31/10/2000</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Schönwasser, D</div>

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/11086

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PETRINI J.H.J.: "The Mammalian Mre11-Rad50-Nbs1 Protein Complex: Integration of Functions in the Cellular DNA-Damage Response" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 64, 6 April 1999 (1999-04-06), pages 1264-1269, XP002150324 the whole document -----</p>	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 00/11086

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9838306 A	03-09-1998	EP 0960200 A	01-12-1999